


MECHANISMS OF VASCULAR DISEASE:

A REFERENCE BOOK FOR VASCULAR SPECIALISTS

5



EDITED BY ROBERT FITRIDGE AND MATTHEW THOMPSON
COMPLETELY UPDATED EDITION 2011

BARR SMITH PRESS

Mechanisms of Vascular Disease

Mechanisms of Vascular Disease:

A Reference Book for Vascular Specialists

Robert Fitridge

The University of Adelaide, The Queen Elizabeth Hospital, Woodville, Australia

Matthew Thompson

St George's Hospital Medical School, London, UK



BARR SMITH PRESS

An imprint of
The University of Adelaide Press

Published in Adelaide by

The University of Adelaide, Barr Smith Press
Barr Smith Library
The University of Adelaide
South Australia 5005
press@adelaide.edu.au
www.adelaide.edu.au/press

The University of Adelaide Press publishes peer-reviewed scholarly works by staff via Open Access online editions and print editions.

The Barr Smith Press is an imprint of the University of Adelaide Press, reserved for scholarly works which are not available in Open Access, as well as titles of interest to the University and its associates. The Barr Smith Press logo features a woodcut of the original Barr Smith Library entrance.

© The Contributors 2011

This book is copyright. Apart from any fair dealing for the purposes of private study, research, criticism or review as permitted under the Copyright Act, no part may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior written permission. Address all inquiries to the Director at the above address.

This CIP cataloguing for this work is as follows;

Mechanisms of vascular disease : a reference book for vascular surgeons / Robert Fitridge, Matthew Thompson, [editors].

1. Blood vessels, Diseases.
 2. Blood vessels, Surgery.
-
- I. Fitridge, Robert
 - II. Thompson, M. M.

For the full Cataloguing-in-Publication data please contact National Library of Australia:
cip@nla.gov.au

ISBN (paperback) 978-0-9871718-2-5

Book design: Midland Typesetters
Cover design: Emma Spoehr, based on a diagram by Dave Heinrich of the Medical Illustration and Media Unit, Flinders Medical Centre
Paperback edition printed by Griffin Press, South Australia

Table of Contents

Contributors vii

Detailed Contents xi

1. Endothelium 1
Paul Kerr, Raymond Tam, Frances Plane (Calgary, Canada)
2. Vascular smooth muscle structure and function 13
David Wilson (Adelaide, Australia)
3. Atherosclerosis 25
Gillian Cockerill, Qingbo Xu (London, UK)
4. Mechanisms of plaque rupture 43
Ian Loftus (London, UK)
5. Current and emerging therapies in atheroprotection 79
Stephen Nicholls, Rishi Puri (Cleveland, USA)
6. Molecular approaches to revascularisation in peripheral vascular disease 103
Greg McMahon, Mark McCarthy (Leicester, UK)
7. Biology of restenosis and targets for intervention 115
Richard Kenagy (Seattle, USA)
8. Vascular arterial haemodynamics 153
Michael Lawrence-Brown, Kurt Liffman, James Semmens, Ilija Sutalo (Melbourne & Perth, Australia)
9. Physiological haemostasis 177
Simon McRae (Adelaide, Australia)
10. Hypercoagulable states 189
Simon McRae (Adelaide, Australia)
11. Platelets in the pathogenesis of vascular disease and their role as a therapeutic target 201
Sandeep Prabhu, Rahul Sharma, Karlheinz Peter (Melbourne, Australia)
12. Pathogenesis of aortic aneurysms 227
Jonathan Golledge, Guo-Ping Shi, Paul Norman (Townsville & Perth, Australia; Boston, USA)
13. Pharmacological treatment of aneurysms 247
Matthew Thompson, Janet Powell (London, UK)
14. Aortic dissection and connective tissue disorders 255
Mark Hamilton (Adelaide, Australia)
15. Biomarkers in vascular disease 277
Ian Nordon, Robert Hincliffe (London, UK)
16. Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon 295
Martin Veller (Johannesburg, South Africa)
17. SIRS, sepsis and multiorgan failure 315
Vishwanath Biradar, John Moran (Adelaide, Australia)
18. Pathophysiology of reperfusion injury 331
Prue Cowled, Robert Fitridge (Adelaide, Australia)
19. Compartment syndrome 351
Edward Choke, Robert Sayers, Matthew Bown (Leicester, UK)
20. Pathophysiology of pain 375
Stephan Schug, Helen Daly, Kathryn Stannard (Perth, Australia)

21. Postamputation pain 389
Stephan Schug, Gail Gillespie
(Perth, Australia)
 22. Treatment of neuropathic pain 401
Stephan Schug, Kathryn Stannard
(Perth, Australia)
 23. Principles of wound healing 423
Gregory Schultz, Gloria Chin,
Lyle Moldauer, Robert Diegelmann
(Florida, USA)
 24. Pathophysiology and principles of
varicose veins 451
Andrew Bradbury (Birmingham, UK)
 25. Chronic venous insufficiency and leg
ulceration: Principles and vascular
biology 459
Michael Stacey (Perth, Australia)
 26. Pathophysiology and principles of
management of the diabetic foot 475
David Armstrong, Timothy Fisher,
Brian Lepow, Matthew White,
Joseph Mills (Tucson, USA)
 27. Lymphoedema – Principles, genetics
and pathophysiology 497
Matt Waltham (London, UK)
 28. Graft materials past and future 511
Mital Desai, George Hamilton
(London, UK)
 29. Pathophysiology of vascular graft
infections 537
Mauro Vicaretti (Sydney, Australia)
- Index 549

List of Contributors

David G Armstrong
The University of Arizona
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Vishwanath Biradar
Intensive Care Unit
The Queen Elizabeth Hospital
Woodville, SA
Australia

Matthew Bown
Department of Vascular Surgery
University of Leicester
Leicester
UK

Andrew W Bradbury
University Department of Vascular Surgery
Birmingham Heartlands Hospital
Birmingham
UK

Edward Choke
Department of Vascular Surgery
University of Leicester
Leicester
UK

Gillian Cockerill
Department of Clinical Sciences
St George's Hospital Medical School
London
UK

Prue Cowled
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Helen Daly
Royal Perth Hospital
Perth, WA
Australia

Mital Desai
University Department of Vascular Surgery
Royal Free Hospital
University College
London
UK

Robert F Diegelmann
Department of Biochemistry
Medical College of Virginia
Richmond, VA
USA

Timothy K Fisher
Rashid Centre for Diabetes and Research
Sheikh Khalifa Hospital
Ajmon
UAE

Robert A Fitridge
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Gail Gillespie
Royal Perth Hospital
Perth, WA
Australia

Jonathan Golledge
Vascular Biology Unit
School of Medicine & Dentistry
James Cook University
Townsville, QLD
Australia

George Hamilton
University Department of Vascular Surgery
Royal Free Hospital
University College
London
UK

Mark Hamilton
Department of Surgery
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Robert J Hinchliffe
St George's Vascular Institute
St George's Hospital
London
UK

Richard D Kenagy
Department of Surgery
University of Washington
Seattle, WA
USA

Paul Kerr
Department of Pharmacology
University of Alberta
Alberta
Canada

Michael MD Lawrence-Brown
Curtin Health Innovation Research
Institute
Curtin University
Perth, WA
Australia

Brian Lepow
The University of Arizona
Department of Surgery
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Kurt Liffman
CSIRO Material Science & Engineering
and School of Mathematical Sciences
Monash University
Melbourne, Vic
Australia

Ian Loftus
Department of Vascular Surgery
St George's Hospital
London
UK

Mark J McCarthy
Department of Surgery and Cardiovascular
Sciences
University of Leicester
Leicester
UK

Greg S McMahon
Department of Surgery and Cardiovascular
Sciences
University of Leicester
Leicester
UK

Simon McRae
Adult Haemophilia Treatment Centre
SA Pathology
Adelaide, SA
Australia

Joseph L Mills
The University of Arizona
Southern Arizona Limb Salvage Alliance
Tucson, AZ
USA

Lyle Moldawer
Department of Surgery
University of Florida
Gainesville, FL
USA

John L Moran
Faculty of Health Sciences
University of Adelaide
The Queen Elizabeth Hospital
Woodville, SA
Australia

Stephen Nicholls
The Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH
USA

Ian M Nordon
St George's Vascular Institute
St George's Hospital
London
UK

Paul E Norman
School of Surgery
University of WA
Fremantle, WA
Australia

Karlheinz Peter
Baker IDI Heart & Diabetes Institute
Melbourne, Vic
Australia

Frances Plane
Department of Pharmacology
University of Alberta
Alberta
Canada

Janet T Powell
Imperial College
London
UK

Sandeep Prabhu
Baker IDI Heart & Diabetes Institute
Alfred Hospital
Melbourne, Vic
Australia

Rishi Puri
The Heart and Vascular Institute
Cleveland Clinic
Cleveland, OH
USA

Stephan A Schug
Royal Perth Hospital
Perth, WA
Australia

Gregory S Schultz
Department of Obstetrics and Gynaecology
University of Florida
Gainesville, FL
USA

Rahul Sharma
Baker IDI Heart & Diabetes Institute
Alfred Hospital
Melbourne, Vic
Australia

Guo-Ping Shi
Department of Cardiovascular Medicine
Brigham & Women's Hospital
Harvard Medical School
Boston, MA
USA

Michael Stacey
University Department of Surgery
Fremantle Hospital
Fremantle, WA
Australia

Ilija D Sutalo
CSIRO Material Science & Engineering
and Curtin Health Innovation
Research Institute
Curtin University
Highett, Vic

Raymond Tam
Department of Pharmacology
University of Alberta
Alberta
Canada

Matthew Thompson
St Georges Hospital Medical School
London
UK

Martin Veller
Department of Surgery
University of Witwatersrand
Johannesburg
South Africa

Mauro Vicaretti
Department of Vascular Surgery
Westmead Hospital
Westmead, NSW
Australia

Matt Waltham
Academic Department of Surgery
St Thomas' Hospital
London
UK

Matthew L White
Vascular and Endovascular Surgery
University of Arizona
Tucson, AZ
USA

David P Wilson
School of Medical Sciences
Discipline of Physiology
University of Adelaide
Adelaide SA
Australia

Qingbo Xu
Department of Cardiology
Kings College
University of London
UK

Detailed Contents

CHAPTER 1 – ENDOTHELIUM

Paul Kerr, Raymond Tam, Frances Plane

- Introduction 1
- Endothelium-dependent regulation of vascular tone 2
- Angiogenesis 7
- Haemostasis 8
- Inflammation 9
- Conclusions 10
- References

CHAPTER 2 – VASCULAR SMOOTH MUSCLE STRUCTURE AND FUNCTION

David Wilson

- Introduction 13
- Smooth muscle (vascular) structure
- Cytoskeleton 14
- Contractile myofilament
- Functional regulation of vascular smooth muscle: Neuronal, hormonal, receptor mediated 15
- Smooth muscle function 17
- Myofilament basis of smooth muscle contraction and relaxation
- Smooth muscle contraction and relaxation 18
- Ion channels important in the regulation of smooth muscle function
- Regulation of cellular Ca^{2+}
- Sources of cytosolic Ca^{2+} entry 19
- Potassium channels
- Endothelial regulation of smooth muscle vasodilatation 20

Smooth muscle proliferation and vascular remodeling 20

Summary 22

References

CHAPTER 3 – ATHEROSCLEROSIS

Gillian Cockerill, Qingbo Xu

Introduction 25

Atherosclerotic lesions 26

Fatty streaks

Plaque or atheroma

Hypercholesterolemia and oxidised-LDL 27

High-density lipoproteins role in atheroprotection 28

Hypertension and biomechanical stress 29

Biomechanical stress-induced cell death 30

Biomechanical stress and inflammation 31

Biomechanical stress-induced smooth muscle cell proliferation 32

Infections and heat shock proteins

Infections

Heat shock proteins 33

Infections and HSP expression

Infections, sHSP and innate immunity 34

Immune responses 36

MHC class II antigens and T cells

Oxidised LDL as a candidate antigen

HSP60 as a candidate antigen 37

B2-glycoprotein Ib as a candidate antigen

Inflammation

C-reactive protein	38
CD40/CD40L	
Summary and perspectives	39
References	

CHAPTER 4 – MECHANISMS OF PLAQUE RUPTURE

Ian Loftus

Introduction	43
Evidence for the ‘plaque rupture theory’	44
Coronary circulation	
Cerebral circulation	
The role of individual components of the arterial wall	
The endothelium	45
The lipid core	47
The cap of the plaque	49
Smooth muscle cells and collagen production	50
Macrophages and collagen degradation	51
The vessel lumen	56
The role of angiogenesis in plaque rupture	
The role of infectious agents in plaque rupture	57
Risk prediction of plaque instability	58
Imaging	
Blood markers	59
Therapy aimed at plaque stabilisation	
HMG Co-A reductase inhibitors	60
MMP inhibition	
Tissue inhibitors of metalloproteinases (TIMPs)	61
Synthetic MMP inhibitors	
Doxycycline	
ACE inhibitors	
Summary	62
References	63

CHAPTER 5 – CURRENT AND EMERGING THERAPIES IN ATHEROPROTECTION

Stephen Nicholls, Rishi Puri

Background	79
Pathology	
Risk factor modification	80
Statins, LDL lowering and C-reactive protein	
The complexity of HDL	84
The controversy of triglycerides	87
Hypertension	
Risk factor modification in the diabetic patient	89
Glycaemic control	
Global risk factor reduction in diabetics	91
The metabolic syndrome	92
Future targets	93
Conclusion	
References	94

CHAPTER 6 – MOLECULAR APPROACHES TO REVASCULARISATION IN PERIPHERAL VASCULAR DISEASE

Greg S McMahon, Mark J McCarthy

Introduction	103
Mechanisms of vascular growth	
Vasculogenesis	
Angiogenesis	104
Neovessel maturation	105
Microvascular network maturation	106
Arteriogenesis	
Therapeutic induction of vascular growth	107
Delivery of molecular activators of vascular growth	
Angiogenic activators	108
Arteriogenic activators	109
Clinical trials for angiogenic therapy of peripheral vascular disease	
Conclusions	110
References	

CHAPTER 7 – BIOLOGY OF RESTENOSIS AND TARGETS FOR INTERVENTION

Richard Kenagy

Introduction 115

Mechanisms of restenosis

Thrombosis 116

Remodelling

Intimal hyperplasia 123

Sequence of events after injury

Origin of intimal cells 125

Inflammation 126

Role of ECM production 127

The contribution of specific factors to restenosis

Growth factors/cytokines

Inhibitors 128

Coagulation and fibrinolytic factors 129

Matrix metalloproteinases

Extracellular matrix/receptors

Targets for intervention 130

Intracellular signalling molecules

mTOR and microtubules

Transcription factors

miRNA 131

Inflammation targets

Brachytherapy

Extracellular targets and cell-based therapies

Angiotensin pathway

Cell-based therapies 132

Differential effects on endothelium and SMCs

Delivery devices

Prevention versus reversal of restenosis

Conclusions 133

References 134

CHAPTER 8 – VASCULAR ARTERIAL HAEMODYNAMICS

Michael Lawrence Brown, Kurt Liffman, James Semmens, Ilija Sutalo

Introduction 153

Laplace's law of wall of tension 154

Newtonian fluid 155

Non-Newtonian fluid

Poiseuille flow 158

Bernoulli's equation

Young's modulus and pulsatile flow 159

Mass conversion 161

Reynold's number

Arterial dissection, collateral circulation and competing flows 163

Shear stress and pressure 164

Forces on graft systems 165

Case 1 – The cylindrical graft 168

Case 2 – The windsock graft

Case 3 – The curved graft 169

Case 4 – The symmetric bifurcated graft

Computational modelling 170

Recent development and future directions 171

Conclusions 172

References 173

CHAPTER 9 – PHYSIOLOGICAL HAEMOSTASIS

Simon McRae

Introduction 177

Primary haemostasis

Platelets

Platelet adhesion

Platelet activation and shape change 179

Platelet aggregation 180

Interactions between primary and secondary haemostasis 181

Secondary haemostasis

The coagulation cascade 182

Initiation 183

Amplification

Propagation 184

Normal inhibitors of coagulation

Fibrinolysis 185

Conclusions 186

References

CHAPTER 10 – HYPERCOAGULABLE STATES

Simon McRae

Introduction 189

Classification of thrombophilia

Inherited thrombophilia 190

Type 1 conditions

Antithrombin deficiency

Protein C and Protein S deficiency

Type 2 conditions 191

Factor V Leiden

The prothrombin (G20210A) gene mutation

FVL/PGM compound heterozygotes

Other inherited conditions

Acquired thrombophilia 192

Antiphospholipid antibodies

Heparin induced thrombocytopenia

Myeloproliferative disorders 193

Potential reasons for performing thrombophilia testing

Patients with venous thrombosis and their relatives

Providing an understanding of the aetiology of a thrombotic event

Determining risk of recurrence and therefore optimal duration of anticoagulation 194

Determining the need for primary prophylaxis in asymptomatic family members 195

Making decisions regarding the use of the oral contraceptive pill 196

Determining the need for thromboprophylaxis during pregnancy

Patients with arterial thrombosis

Potential detrimental effects of thrombophilia testing 197

Conclusion

References

CHAPTER 11 – PLATELETS IN THE PATHOGENESIS OF

VASCULAR DISEASE AND THEIR ROLE AS A THERAPEUTIC TARGET

*Sandeep Prabhu, Rahul Sharma,
Karlheinz Peter*

Introduction 201

Platelet function – Adhesion and activation

Platelet adhesion 202

Platelet activation 203

Mediators of platelet activation and ‘outside in’ signalling

Thrombin and collagen 204

Adenosine diphosphate (ADP)

Thromboxane A2 (TXA2)

Adrenaline 206

Second messenger systems 207

Physiological consequences of platelet activation

The GP IIb/IIIa receptor and ‘inside-out’ signalling

Granule exocytosis 208

Activation-induced conformational change of platelets

Platelets and atherosclerosis 209

Role of platelets in the initiation of the atherosclerosis

Role of the platelets in the progression of the atherosclerosis

Role of platelets in vulnerable plaques and plaque rupture

Current and future anti-platelet agents 210

Aspirin (salicylic acid)

Thienopyridines 211

Clopidogrel

Prasugrel 213

Ticlopidine

Ticagrelor

GPIIb/IIIa Antagonists

Other anti-platelet agents and promising new developments 214

Platelet function testing 215

Light-transmission aggregometry

Whole blood aggregometry 217
 VerifyNow® Assay
 Flow cytometry 218

References

CHAPTER 12 – PATHOGENESIS OF AORTIC ANEURYSMS

*Jonathan Golledge, Guo-Ping Shi,
 Paul E Norman*

Introduction 227

Differences between thoracic and abdominal aortic aneurysms 228

Summary of current theories and stages of AAA evolution

Atherosclerosis and AAA

Immune mechanisms in AAA 229

Extracellular matrix dysfunction 232

Infection 233

Biomechanical forces

Angiogenesis

Intra-luminal thrombus

Extracellular matrix proteolysis 234

Genetics 236

AAA rupture 237

Biomechanical factors in aneurysms rupture

The role of enzymes in AAA rupture

Role of intraluminal thrombus in aneurysm rupture 238

Future research

References

CHAPTER 13 – PHARMACOLOGICAL TREATMENT OF ANEURYSMS

Matthew Thompson, Janet T Powell

Background 247

Screening programmes

Pathophysiology 248

Therapeutic strategies

Beta blockade

Modification of the inflammatory

response 249

Non-steroidal anti-inflammatories

Matrix metalloproteinase (MMP)

inhibition

Anti-chlamydial therapy 250

Drugs acting on the renin/angiotensin axis

HMG Co-A reductase inhibitors 251

The future – Data from recent

experimental studies

References

CHAPTER 14 – PATHOPHYSIOLOGY OF AORTIC DISSECTION AND CONNECTIVE TISSUE DISORDERS

Mark Hamilton

Introduction 255

Embryology of thoracic aorta and arch vessels

Haemodynamics of thoracic compared to abdominal aorta 257

Sizes of normal aorta

Classification of aortic syndromes

Acute/Chronic

DeBakey classification of class 1 dissection – Type 1, 2, and 3

Stanford classification 258

European task force

Pathogenesis of thoracic aortic dissection

Classical thoracic aortic dissection (class 1 dissection) 260

Intramural haematoma (class 2 aortic dissection) 261

Penetrating aortic ulcer (class 4 aortic dissection) 262

Complications of acute aortic syndromes 263

Visceral ischaemia /malperfusion syndromes

Fate of the false lumen

Aneurysmal degeneration and rupture 264

Connective tissue disorders and acute aortic syndromes

Marfan syndrome	
Fibrillin and Marfan syndrome	265
The role of transforming growth factor beta in development of the vascular system in health and disease	266
Ehlers-Danlos syndrome	267
Diagnosis of Ehlers-Danlos syndrome	268
Loeys-Deitz syndrome	270
Familial thoracic aortic aneurysm disease	271
Bicuspid aortic valve	273
Turners Syndrome	
Summary	274
Reference list	

CHAPTER 15 – BIOMARKERS IN VASCULAR DISEASE

Ian M Nordon, Robert J Hinchliffe

Introduction	277
What is a biomarker?	
Types of biomarkers	
A classical clinical example	278
Potential value of biomarkers in vascular disease	279
Biomarker discovery steps	280
AAA biomarkers	
Circulating extracellular matrix markers	281
Matrix-degrading enzymes	283
Proteins associated with thrombosis	
Markers of inflammation	284
Biomarkers of AAA rupture	285
Biomarkers following endovascular repair	
Inflammation	287
Lipid accumulation	
Apoptosis	
Thrombosis	
Proteolysis	288
Challenges in biomarkers discovery	
Future work	
Conclusion	289
References	

CHAPTER 16 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VASCULITIS AND RAYNAUD'S PHENOMENON

Martin Veller

Vasculitides	295
Introduction	
Classification of vasculitides	296
Clinical presentation of vasculitides	
Investigations of vasculitides	
Principles of treatment of vasculitides	297
The vasculitides of specific interest to vascular surgeons	298
Giant cell arteritis	
Takayasu's arteritis	299
Thromboangitis obliterans (Buerger's disease)	300
Behcet's disease	301
Polyarteritis nodosa	302
Vasculitides secondary to connective tissue diseases	303
Systemic lupus erythematosus (SLE)	
Antiphospholipid antibody syndrome (APS)	304
Rheumatoid arthritis	305
Scleroderma	
Infective vasculitides	306
Human immunodeficiency virus (HIV)	
Pathophysiology and principles of Raynaud's phenomenon	307
Prevalence of Raynaud's phenomenon	308
Clinical findings in Raynaud's phenomenon	309
Diagnosis of Raynaud's phenomenon	
Prognosis	310
Treatment	
Recommendations	311
References	312

CHAPTER 17 – SIRS, SEPSIS AND

MULTIORGAN FAILURE*Vishwanath Biradar, John Moran***Epidemiology 315****Historical perspectives and definition 316****Risk factors for sepsis 317**

Causative agents

Pathophysiology of sepsis

innate immunity and toll-like receptors (TLRs) 319

Proinflammatory response

Coagulation cascade

Multorgan dysfunction syndrome (MODS) 320

Epithelial and endothelial dysfunction

Immune suppression and apoptosis

Sepsis, circulatory failure and organ dysfunction

Management 322

Steroids 323

Recombinant human activated protein C (rhAPC) 324

Glucose control 325

Renal replacement therapy

3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors (HMG-CoA) 326

Other adjuvant therapies in sepsis

Cytokines and anticytokine therapies

Pooled immunoglobulin (IVIG)

Acute respiratory distress syndrome (ARDS) 327

References**CHAPTER 18 –
PATHOPHYSIOLOGY OF
REPERFUSION INJURY***Prue Cowled, Rob Fitridge***Introduction 331****Ischaemia**

ATP and mitochondrial function

Gene expression during ischaemia 332

Reperfusion 333

Reactive oxygen species

Eicosanoids 334

Nitric Oxide 335

Endothelin 336

Cytokines

Neutrophil and endothelial interactions 338

Complement activation 340

Tissue destruction 341

Proteases and metalloproteinases

Apoptotic cell death during ischaemia-reperfusion injury

No-reflow phenomenon 342

Therapeutic approaches to IRI

Ischaemic preconditioning

Ischaemic post-conditioning 343

Conditioning effects of volatile anaesthetics

Pharmacological treatments 344

Summary 345**References****CHAPTER 19 – COMPARTMENT
SYNDROME***Edward Choke, Robert Sayers, Matthew Bown***Definition 351****Acute limb compartment syndrome**

Incidence

Anatomy/physiology 352

Aetiology/pathophysiology

Clinical presentation 354

Investigation 355

Treatment 357

Complication of LCS 359

Outcome 360

Acute abdominal compartment syndrome

Incidence 361

Aetiology

Pathological effects of raised intra-abdominal pressure 362

Clinical presentation 363

Investigation

Treatment 364

Complications of surgical decompression

Outcome 367

References 368

CHAPTER 20 – PATHOPHYSIOLOGY OF PAIN

Stephan Schug, Helen Daly, Kathryn Stannard

Introduction 375

Peripheral mechanisms

Nociception/transduction

Conduction 376

Spinal cord mechanisms

Ascending systems 377

Descending control

Pain modulation 378

Peripheral sensation

Central sensitisation in the dorsal horn

Neuropathic pain 379

Mechanisms of neuropathic pain

Peripheral mechanisms

Spontaneous ectopic discharge

Altered gene expression

Spared sensory neurons

Involvement of the sympathetic nervous system 380

Collateral sprouting

Effects of bradykinin

Central mechanisms

Wind up

Central sensitization 381

Central disinhibition

Expansion in receptive field size (recruitment)

Immediate early gene expression

Anatomical re-organisation of the spinal cord

Contribution of glial cells to pain conditions 382

Symptoms of neuropathic pain

Stimulus-dependent pain

Stimulus-independent pain 383

Sympathetically maintained pain (SMP)

Neuropathic pain syndromes

Peripheral neuropathies

Central neuropathies 385

References

CHAPTER 21 – POST-AMPUTATION PAIN

Stephan Schug, Gail Gillespie

Introduction 389

Classification and incidence of post-amputation pain syndromes

Stump pain

Phantom sensation 390

Phantom limb pain

Pathophysiology of post-amputation pain syndromes

Peripheral factors

Spinal factors 391

Supraspinal factors

Current pathophysiological model of post-amputation pain syndromes 392

Prevention of post-amputation pain

Perioperative lumbar epidural blockade

Peripheral nerve blockade 393

NMDA antagonists

Evaluation of the patient with post-amputation pain syndromes

Examination

Therapy of post-amputation pain syndromes 394

Calcitonin

Ketamine

Analgesic and Co-analgesic compounds

Opioids 395

Gabapentin

Clonazepam

Lidocaine

Carbamazepine

Tricyclic antidepressants (TCA)

Selective serotonin reuptake inhibitors

Baclofen

Capsaicin

Symptomatic treatment of pain components 396

Neuropharmacological therapies

Invasive therapies
 Electroconvulsive therapy (ECT)
 Nerve blockade
 Spinal cord stimulation
 Implantable intrathecal delivery systems
 Dorsal root entry zone (DREZ) lesions
 Psychological therapy 397

Future aims

References

CHAPTER 22 – TREATMENT OF NEUROPATHIC PAIN

Stephan Schug, Kathryn Stannard

Introduction 401

Principles of treatment

Pharmacological treatment 402

Opioids

Recommendations for clinical use of opioids

Tramadol

Mechanism of action

Efficacy 403

Adverse effects

Recommendations for clinical use of tramadol in neuropathic pain

Antidepressants

Tricyclic antidepressants (TCAs)

Mechanism of action 404

Adverse effects

Selective serotonin re-uptake inhibitors (SSRIs)

Serotonin/Noradrenaline reuptake inhibitors (SNRIs) 405

Recommendations for clinical use of antidepressants as analgesics

Anticonvulsants

Mechanism of action 406

Individual medications

Clonazepam

Gabapentin

Pregabalin 407

Carbamazepine

Sodium valproate 408

Phenytoin

Lamotrigene

Recommendations for clinical use of anticonvulsants as analgesics

Local anaesthetics and antiarrhythmics 409

Mechanism of action

Lignocaine

Mexiletine

Recommendations for clinical use of lignocaine and mexiletine in neuropathic pain

N-methyl-D-aspartate-receptor antagonists (NMDA)

Ketamine 410

Other NMDA antagonists

Miscellaneous compounds for systemic use

Clonidine

Efficacy

Baclofen

Levodopa 411

Cannabinoids

Topical treatments

Lignocaine 5% medicated plaster

Capsaicin 412

Mechanism of action

Efficacy

Non-pharmacological therapy

Transcutaneous electrical nerve stimulation (TENS)

Spinal cord stimulation (SCS) 413

Sympathetic nerve blocks

Neurosurgical destructive techniques

Cognitive behaviour therapy

References 414

CHAPTER 23 – PRINCIPLES OF WOUND HEALING

Gregory Schultz, Gloria Chin, Lyle Moldawer, Robert Diegelmann

Introduction 423

Phases of acute wound healing

Haemostasis

- Inflammation 426
 - Neutrophils 427
 - Macrophages 428
- Proliferative phase 429
 - Fibroblast migration 430
 - Collagen and extracellular matrix production
 - Angiogenesis 431
 - Granulation 432
 - Epithelialization
 - Remodelling 433
- Summary of acute wound healing 435
- Comparison of acute and chronic wounds**
 - Normal and pathological responses to injury
 - Biochemical differences in the molecular environments of healing and chronic wounds 436
 - Biological differences in the response of chronic wound cells to growth factors 439
- From bench to bedside**
 - Role of endocrine hormones in the regulation of wound healing
 - Molecular basis of chronic non-healing wounds
 - Chronic venous stasis ulcers 441
 - Pressure ulcers
- Future concepts for the treatment of chronic wounds 442**
 - Bacterial biofilms in chronic wounds 443
- Conclusion 445**
- References**

CHAPTER 24 – PATHOPHYSIOLOGY AND PRINCIPLES OF MANAGEMENT OF VARICOSE VEINS

Andrew Bradbury

- Introduction 451**
- Anatomy**
- Histology 452**
- Physiology**

- Varicose veins 453**
- Valvular abnormalities**
- Muscle pump failure 455**
- Venous recirculation**
- Recurrent varicose veins**
 - New varicose veins
 - Persistent varicose veins
 - True recurrent varicose veins 456
- Cellular and molecular biology of varicose veins**
- Conclusion 457**
- References**

CHAPTER 25 – CHRONIC VENOUS INSUFFICIENCY AND LEG ULCERATION: PRINCIPLES AND VASCULAR BIOLOGY

Michael Stacey

- Definitions 459**
 - Chronic venous insufficiency
 - Leg ulceration
 - Assessment of cause of leg ulceration 460
- Epidemiology 461
- Pathophysiology
 - Venous abnormality
 - Effect of ambulatory venous hypertension on the tissues in the leg 463
 - Influence of venous disease on the wound healing process 465
 - Genetic associations with venous ulceration 466
- Assessment of venous function 467**
- Treatment of venous ulceration**
 - Compression therapy
 - Dressings 468
 - Surgery
 - Prevention of venous ulcer recurrence 470
 - Sclerotherapy and other techniques to obliterate surface and perforating veins
 - Other therapies 471
- References**

CHAPTER 26 –
PATHOPHYSIOLOGY AND
PRINCIPLES OF MANAGEMENT
OF THE DIABETIC FOOT

*David Armstrong, Timothy Fisher, Brian
Lepow, Matthew White, Joseph Mills*

- Introduction** 475
- Pathophysiology of the diabetic foot** 476
- Neuropathy
 - Structural abnormalities/gait abnormalities
 - Angiopathy 478
- Diagnosis**
- History and rapid visual screening
 - Neurological examination 479
 - Monofilament testing
 - Vibration testing
 - Dermatologic examination 480
 - Anatomy of occlusive disease – vascular examination
 - Prediction of wound healing: assessment of perfusion 481
 - Arterial imaging
 - Soft tissue imaging 482
- Classification systems** 483
- Diabetes mellitus foot risk classification
 - University of Texas wound classification system
- Clinical problems and principles of management** 484
- Ulceration
 - Epidemiology and risk factors
 - Offloading
 - Non-vascular surgical treatment 485
 - Class I – Elective 486
 - Class II – Prophylactic
 - Class III – Curative
 - Class IV – Emergency (urgent)
 - Post-operative management
 - Infections 487
 - Charcot arthropathy
- Prevention** 490
- Conclusion** 492
- References**

CHAPTER 27 – LYMPHOEDEMA
– PRINCIPLES, GENETICS AND
PATHOPHYSIOLOGY

Matt Waltham

- Introduction** 497
- Classification of lymphoedema**
- Classification of primary lymphoedema 498
- The genetics of lymphangiogenesis in primary lymphoedema** 500
- Milroy's disease
 - Lymphoedema – distichiasis syndrome 501
 - Hypotrichosis – lymphoedema – telangiectasia syndrome 502
 - Meige disease (primary non-syndromic lymphoedema)
 - Other primary lymphoedema disorders 503
- Structure and development of the lymphatic circulation**
- Clinical aspects of lymphoedema** 505
- Summary**
- References**

CHAPTER 28 – GRAFT
MATERIALS PAST AND FUTURE

Mital Desai, George Hamilton

- The pathophysiology of graft healing** 511
- The peri-anastomotic area
 - Healing of prosthetic grafts 512
 - The healing process of the anastomosis
 - Graft porosity and permeability
- Physical properties of prosthetic materials** 514
- Tubular compliance
 - Anastomotic compliance mismatch
 - The compliance hypothesis of graft failure
- Synthetic grafts** 515
- Newer developments of Dacron grafts
 - Modifications and newer developments of PTFE grafts 517
 - Polyurethane grafts

Newer developments of polyurethane vascular grafts	518
Biological vascular grafts	519
Newer developments of biological vascular grafts	520
Prosthetic graft modifications	
Modifications to reduce graft infection	
Modifications to improve patency	521
Nanocomposite grafts	
Endothelial cell seeding	522
Single stage seeding	
Two stage seeding	
Vascular tissue engineering	
Non-degradable polymer and cell seeding	523
Bioresorbable and biodegradable polymers	
Combined bioresorbable and tissue engineered grafts	524
Mechanical conditioning of seeded vascular cells	
Alternative scaffolds	
Tissue-engineered grafts	525
Graft materials for aortic endografts	526
The future	
References	527

CHAPTER 29 – PATHOPHYSIOLOGY OF VASCULAR GRAFT INFECTIONS

Mauro Vicaretti

Introduction	537
Natural history of prosthetic vascular graft infections	
Mechanism of graft contamination at operation	538
Pathogenesis of graft infections	
Bacteriology of vascular graft infections	
Investigations for detection of prosthetic graft infections	539
History and physical examination	
Laboratory investigations	
Diagnostic imaging	540
Management of prosthetic graft infections	
Prevention	
Reduction of prosthetic vascular graft infection with rifampicin bonded gelatin sealed Dacron	541
Established infection	
Antibiotic therapy	
Operative management	
Conclusion	542
References	

Acknowledgements

The Editors gratefully acknowledge the outstanding contributions of each Author involved in this reference book. We would also like to acknowledge the invaluable efforts of Ms Sheona Page who has worked tirelessly on this project. We would also like to thank Prue Cowled PhD and Ms Cayley Wright for their assistance.

Abbreviation List

a1-PI	a1-protease inhibitor
5-HT	5-Hydroxytryptamine/Serotonin
AAA	Abdominal aortic aneurysm
AAS	Acute aortic syndrome
AAV	Adeno-associated viruses
ACE	Angiotensin converting enzyme
ACS	Acute coronary syndrome
ACS	Abdominal compartment syndrome
ACTH	Adrenocorticotrophic hormone
ADAMTS	A disintegrin and metalloproteinase with thrombospondin motifs
ADP	Adenosine diphosphate
AIDS	Acquired immune deficiency syndrome
ALI	Acute lung injury
AMP	Adenosine monophosphate
AMPA	α -amino-3 hydroxy-5-methylisoxazole
ANA	Anti-nuclear antibody
ANCA	Anti-neutrophil cytoplasmic antibody
AOD	Aortic occlusive disease
AP1	Activated protein 1
APC	Activated protein C
APC	Antigen presenting cell
APLAS	Antiphospholipid antibody syndrome
ApoAI	Apolipoprotein AI
ApoE	Apolipoprotein E
APS	Antiphospholipid antibody syndrome
APTT	Activated partial thromboplastin time

ARDS	Acute respiratory distress syndrome
AT	Antithrombin
ATP	Adenosine triphosphate
AVP	Ambulatory venous thrombosis
β 2-GPI	β 2-glycoprotein Ib
bFGF	Basic fibroblast growth factor
BKCa	Large conductance calcium activated potassium channel
BMPs	Bone morphogenetic proteins
BMS	Bare metal stent
CAD	Coronary artery disease
CaM	Calmodulin
CAM	Cell adhesion molecule
cAMP	Cyclic adenosine monophosphate
CCK	Cholecystokinin
cGMP	Cyclic guanine monophosphate
CD	Cluster of differentiation
CD40L	Cluster of differentiation 40 ligand
CEA	Carotid endarterectomy
CETP	Cholesteryl ester transfer protein
CFD	Computational fluid dynamics
CG	Cationized gelatin
CGRP	Calcitonin gene regulated peptide
CHD	Coronary heart disease
CI	Confidence interval
CIMT	Carotid intimal-media thickness
c-JNK	c-Jun N-terminal kinase
CK-MB	Creatinine kinase (Myocardial specific)
CNCP	Chronic noncancer pain
cNOS	Constitutive nitric oxygen synthase enzyme
COX-1	Cyclooxygenase-1
COX-2	Cyclooxygenase-2
CROW	Charcot restraint orthotic walker
CRRT	Continuous renal replacement therapy

CRP	C-reactive protein
CRPS	Complex regional pain syndromes
CT	Computational tomography
CTA	Computed tomographic angiography
CTD	Connective tissue disorders
CTGF	Connective tissue growth factor
CYP	Cytochrome P450
CVD	Cardiovascular disease
CVI	Chronic venous insufficiency
DAG	Diacylglycerol
DES	Drug-eluting stent
DRG	Dorsal root ganglion
DNA	Deoxyribonucleic acid
DSA	Digital subtraction arteriography
DTS	Dense tubular system
DVT	Deep vein thrombosis
EC	Endothelial cell
ECM	Extracellular matrix
EDCF	Endothelium-derived contracting factor
EDH	Endothelium-dependent hyperpolarisation
EDS	Ehlers-Danlos syndrome
EET	Epoxyeicosatrienoic acids
ELAM-1	Endothelial-leukocyte adhesion molecule-1
ELG	Endoluminal grafts
ELISA	Enzyme linked immunosorbent assay
E_K	Equilibrium potential
E_M	Membrane potential
eNOS	Endothelial nitric oxide synthase enzyme
EPC	Endothelial progenitor cells
EPCR	Endothelial protein C receptor
ePTFE	Expanded polytetrafluoroethylene
ERK	Extracellular signal-regulated kinase
ESR	Erythrocyte sedimentation rate

ET	Essential thrombocytosis
ET-1	Endothelin 1
EVAR	Endovascular aortic aneurysm repair
EVLA	Endovenous LASER ablation
FDA	Food and drug administration
FDPs	Fibrin degradation products (soluble)
FGF	Fibroblast growth factor
FGF-2	Fibroblast growth factor 2
FMN	Flavin mononucleotide
FVL	Factor V Leiden
GABA	Gamma-aminobutyric acid
GABA B	Gamma-aminobutyric acid subtype B
G-CSF	Granulocyte colony stimulating factor
GMCSF	Granulocyte-macrophage colony stimulating factor
GP	Glycoprotein
GPCR	G-protein coupled receptor
GSV	Great saphenous vein
HDL	High density lipoprotein
HDL-C	High density lipoprotein cholesterol
HIF	Hypoxia inducible factor
HIT	Heparin induced thrombocytopenia
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigen
HMG Co-A	Hydroxymethylglutaryl coenzyme-A
HMW	High molecular weight
HPETE	Hydroperoxyeicosatetraenoic acid
HETE	Hydroxyeicosatetraenoic acids
HR	Hazard ratio
hsCRP	High-sensitive C-reactive protein
HSP	Heat shock protein
HUV	Human umbilical vein
IAH	Intra-abdominal hypertension

IAP	Intra-abdominal pressure
IAPP	Intra-abdominal perfusion pressure
ICAM-1	Inter-cellular adhesion molecule-1
ICAM-2	Inter-cellular adhesion molecule-2
ICP	Intra-compartmental pressure
ICU	Intensive care unit
IFN	Interferon
IGF-1	Insulin-like growth factor-1
IHD	Ischemic heart disease
IL	Interleukin
IL-1	Interleukin-1
IL-1 α	Interleukin-1 alpha
IL-1 β	Interleukin-1 beta
IL-6	Interleukin-6
IL-8	Interleukin-8
ILT	Intraluminal thrombus
IKCa	Intermediate conductance calcium-activated potassium channels
IMH	Intramural haematoma
IMP	Inosine monophosphate
iNOS	Inducible nitric oxide synthase enzyme
IP(3)	1,4,5-inositol triphosphate
IRI	Ischemia reperfusion injury
IVIG	Intravenous pooled immunoglobulin
IVUS	Intravascular ultrasound
KGF	Keratinocyte growth factor
KGF-2	Keratinocyte growth factor-2
LAP	Latency associated peptide
LCS	Limb compartment syndrome
LDL	Low density lipoprotein
LDS	Loeys-Dietz syndrome
LLC	Large latent complex
LEC	Lymphatic endothelial cells

LFA-1	Lymphocyte function-associated antigen-1
LO	Lipoxygenase
LOX	Lysyl oxidase
LOPS	Loss of protective sensation
LPA	Lysophosphatidic acid
LPS	Lipopolysaccharide
LTA	Lipoteichoic acid
LTGFBP	Latent TGF binding protein
MAC-1	Macrophage-1 antigen
MAPK	Mitogen activated protein kinase
MCP-1	Monocyte chemoattractant protein-1
M-CSF	Macrophage-colony stimulating factor
MFS	Marfan syndrome
MHC	Major histocompatibility
MI	Myocardial infarction
MIP-1	Macrophage inflammatory protein-1
MLC ₂₀	Myosin light chain ₂₀
MLCK	Myosin light chain kinase
MLCP	Myosin light chain phosphatase
MMP	Matrix metalloproteinase
MODS	Multiple organ dysfunction syndrome
MRA	Magnetic resonance angiography
MRI	Magnetic resonance imaging
mRNA	Messenger RNA
MRSA	Methicillin resistant <i>Staphylococcus aureus</i>
MRSE	Methicillin resistant <i>Staphylococcus epidermidis</i>
MRTA	Magnetic resonance tomographic angiography
MTHFR	Methylenetetrahydrofolate reductase
MT-MMP	Membrane-type MMP
MVPS	Mitral valve prolapse syndrome
NADPH	Nicotinamide adenine dinucleotide phosphate
NGF	Nerve growth factor

NFκB	Nuclear factor kappa B
NiTi	Nitinol
NJP	Non-junctional perforators
NMDA	N-methyl-D-aspartate
NNH	Number needed to harm
NNT	Number needed to treat
NO	Nitric oxide
NOS	Nitric oxide synthase enzyme
NSAID	Non-steroidal anti-inflammatory drug
NV	Neovascularisation
OCP	Oestrogen/progesterone contraceptive pill
OPN	Osteopontin
OPG	Osteoprotegerin
OR	Odds ratio
OxLDL	Oxidised low density lipoprotein
PAD	Peripheral arterial disease
PAF	Platelet activating factor
PAI	Plasminogen activator inhibitor
PAI-1	Plasminogen activator inhibitor-1
PAR	Protease activated receptor
PAR-1	Protease activated receptor-1
PAR-4	Protease activated receptor-4
PAU	Penetrating aortic ulcer
PC	Protein C
PCA	Poly (carbonate-urea) urethane
PCI	Percutaneous coronary intervention (angioplasty)
PCWP	Pulmonary capillary wedge pressure
PDGF	Platelet-derived growth factor
PDGFβ	Platelet-derived growth factor-β
PDS	Polydioxanone
PECAM-1	Platelet-endothelial cell adhesion molecule-1
PEDF	Pigment epithelium-derived factor
PES	Paclitaxel-eluting stent

PET	Positron emission tomography
PF4	Platelet factor 4
PGI ₂	Prostacyclin
PGG ₂	Prostaglandin G ₂
PGH ₂	Prostaglandin H ₂
PGEI ₂ /PGI ₂	Prostaglandin I ₂
PGN	Peptidoglycan
PHN	Postherpetic neuropathy
PHZ	Para-anastomotic hyper-compliant zone
PI3K	Phosphatidylinositol 3-kinase
PIP2	Phosphatidylinositol 4,5-bisphosphate
PLC	Phospholipase C
PLOD	Procollagen lysyl hydroxylase
PMCA	Plasma membrane Ca ²⁺ APTases
PMN	Polymorphonuclear leukocyte
POSS	Polyhedral oligomeric silsesquioxanes
PPAR	Peroxisomal proliferation activating receptor
PPI	Proton pump inhibitor
PRV	Polycythaemia rubra vera
PS	Protein S
PSGL-1	P-selectin glycoprotein ligand-1
PT	Prothombin time
PTCA	Percutaneous coronary angioplasty
PTFE	Polytetrafluoroethylene
PTS	Post-thrombotic syndrome
PUFA	Polyunsaturated fatty acid
PVI	Primary valvular incompetence
rAAA	Ruptured AAA
Rac	Ras activated cell adhesion molecule
RANTES	Regulated upon activation, normal T cell expressed and secreted
RAS	Renin angiotensin system
RCT	Randomised controlled trial

RF	Rheumatoid factor
RFA	Radiofrequency ablation
rhAPC	Recombinant human activated protein C
RNA	Ribonucleic acid
ROS	Reactive oxygen species
RR	Relative risk
RSD	Reflex sympathetic dystrophy
S1P	Sphingosine-1-phosphate
SAPK	Stress-activated protein kinase
SCF	Stem cell factor
SCS	Spinal cord stimulation
ScvO2	Superior vena cava venous oxygen saturation
SDF-1	Stromal-cell-derived factor-1
SERCA	Sarco/endoplasmic reticulum CaATPases
SEP	Serum elastin peptides
SES	Sirolimus-eluting stent
SEPS	Subfascial endoscopic perforator surgery
SFA	Superficial femoral artery
SFJ	Sapheno-femoral junction
SIRS	Systemic inflammatory response syndrome
SKCa	Small conductance calcium-activated potassium channels
SLE	Systemic lupus erythematosus
SMA	Smooth muscle alpha actin
SMC	Smooth muscle cell
SMP	Sympathetically maintained pain
SNARE	Soluble N-ethylmaleimide-sensitive factor activating protein receptors
SNP	Single nucleotide polymorphisms
SNRI	Serotonin/Noradrenaline reuptake inhibitors
SPJ	Sapheno-popliteal junction
SPP	Skin perfusion pressure
SR	Sarcoplasmic reticulum
SSRIs	Selective serotonin re-uptake inhibitors
SSV	Small saphenous vein

SVT	Superficial thrombophlebitis
STIM1	Stromal interacting molecule 1
T α CE	TNF α converting enzyme
TAAD	Thoracic aortic aneurysm disease
TAD	Thoracic aortic dissection
TAFI	Thrombin-activatable fibrinolysis inhibitor
Tc-99 MDP	Technetium-99 methylene diphosphonate
TCA	Tricyclic antidepressant
TCC	Total contact cast
TCR	T-cell receptor
TENS	Transcutaneous electrical nerve stimulation
TF	Tissue factor
TFPI	Tissue factor pathway inhibitor
TGF	Transforming growth factor
TGF- α	Transforming growth factor-alpha
TGF- β	Transforming growth factor-beta
TGL	Triglycerides
Th	T helper
TIA	Transient ischemic attack
TIMP	Tissue inhibitors of metalloproteinase
TLR	Toll-like receptors
TNF	Tumour necrosis factor
TNF- α	Tumour necrosis factor-alpha
tPA	Tissue-type plasminogen activator
TRP	Transient receptor potential
TRPC	Transmembrane receptor potential canonical
TRPV1	Transmembrane receptor potential Vanilloid-type
TXA2	Thromboxane A2
uPA	Urokinase
UT	University of Texas
VCAM	Vascular cell adhesion molecule
VCAM-1	Vascular cell adhesion molecule-1
VEGF	Vascular endothelial growth factor

VEGF-R	Vascular endothelial growth factor receptor
VIP	Vasoactive intestinal peptide
VLA-1	Very late activating antigen-1
VOCC	Voltage operated calcium channels
VPT	Vibratory perception threshold
VSMC	Vascular smooth muscle cells
VTE	Venous thromboembolism
VV	Varicose veins
vWF	von Willebrand factor
XO	Xanthine oxidase

5 • Current and Emerging Therapies in Atheroprotection

STEPHEN NICHOLLS, RISHI PURI

The Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio

BACKGROUND

The global epidemic of cardiovascular disease (CVD) continues to rise, with atherosclerotic CVD remaining the lead cause of morbidity and mortality worldwide, comprising of 29% of all global deaths in 2003. A majority of these deaths were directly caused by coronary artery disease (CAD) or strokes.¹ It is estimated that up to 50% of all deaths and disability due to CAD and strokes could be curtailed by a number of lifestyle and therapeutic approaches that directly target major cardiovascular risk factors.

Atherosclerosis is a systemic disease process involving multiple vascular territories. The presence of established vascular disease, regardless of the territory involved, portends the greatest risk of incident cardiovascular events. The prevalence of asymptomatic coronary stenoses of greater than 50% angiographic severity in non-disabling ischaemic stroke patients has recently been estimated to be 20%,² and those patients afflicted with peripheral arterial disease have a probability of death due to CAD and stroke of 55% and 11% respectively.³ Given the significant systemic plaque burden in these patients coupled with corresponding high event rates, various anti-atherosclerotic and vascular protective therapies have the potential to significantly lower absolute clinical event rates.

PATHOLOGY

Atherosclerosis is a chronic inflammatory condition, characterised by the accumulation of inflammatory cells, lipid and apoptotic material within the arterial wall. The endothelial cell layer, a single cell layer lining the lumen of the vasculature, serves to regulate permeability of the arterial wall, vascular tone and tendency for thrombus formation. Endothelial dysfunction therefore results in altered permeability of the vessel wall, increased vascular reactivity with vasoconstriction and the promotion of a number of prothrombotic substances. Such abnormalities are inherently promoted by the reduced bioavailability of nitric oxide, the principal product of the endothelium. Following transmigration across the endothelial layer, migrated monocytes transform into macrophages, which engulf extracellular lipid to become foam cells, which accumulate to form a fatty streak, considered the earliest macroscopic evidence of atherosclerosis.⁴ Local smooth muscle cell migration results in collagen production, forming a fibrous cap, which separates the enlarging inflammatory and lipid milieu from the circulating blood stream. The ongoing accumulation of inflammatory cells, lipid and apoptotic material covered by a strong fibrous cap represents a mature atherosclerotic plaque.⁴ Many

atherosclerotic plaques remain clinically quiescent, however some plaques may progress to an advanced stage, characterised by progressive lumen encroachment, aneurysm formation and plaque rupture. The latter two processes are mediated by the degeneration of the extracellular collagen matrix, which in turn is driven by activated matrix metalloproteinase enzymes.⁵ Furthermore, plaque neovascularisation (with the adventitial proliferation of vaso-vasorum) leading to repeated intraplaque haemorrhage is now widely recognised as an important mediator of plaque progression and instability.⁶

The degradation of collagen within the fibrous cap leads to a reduction in the tensile strength, which appears more pronounced at the shoulders regions of the plaque. Higher shear stress at these shoulder region, further predispose the thinned fibrous cap to erosion or rupture. This exposes plaque components (including the highly thrombogenic tissue factor) to the circulating blood stream, culminating in the activation and aggregation of platelets and the coagulation cascade, leading to local thrombus formation. This thrombus may embolise downstream, or result in local occlusion of the arterial lumen to blood flow, with resulting acute ischaemia.⁷

Anti-atherosclerotic therapies are administered for either the primary prevention of cardiovascular events, or to prevent the recurrence of events in those patients with established vascular disease. This chapter will review the role of various strategies that have shown clinical evidence of their atheroprotective effects for the prevention of cardiovascular disease.

RISK FACTOR MODIFICATION

Population studies have established an association of the presence of a number of modifiable cardiovascular risk factors

with increased risk for the development of CVD.^{8,9} These risk factors include: (1) elevated plasma concentrations of various atherogenic lipoproteins, which include low-density lipoprotein cholesterol (LDL-C), lipoprotein (a) and triglycerides (TGL); (2) reduced plasma concentrations of high-density lipoprotein cholesterol (HDL-C); (3) hypertension; (4) diabetes; (5) smoking; and (6) obesity and the associated metabolic syndrome. Mechanistic studies, primary and secondary prevention clinical studies and atherosclerosis imaging studies, have demonstrated significant benefits following the reduction of pro-atherogenic lipoproteins, elevation of HDL-C and treating hypertension, whilst the aggressive glucose lowering for reducing cardiovascular events remains controversial.

TABLE 5.1: Modifiable atherogenic risk factors

- Elevated atherogenic lipoproteins:
LDL-C
TGL levels
Lipoprotein (a)
Chylomicron remnant particles
- Reduced HDL-C levels
- Hypertension
- Diabetes mellitus
- Obesity
- Smoking

Statins, LDL lowering and C-Reactive Protein

In population studies with extensive follow-up, plasma concentrations of LDL-C have been shown to be a strong and independent predictor of future cardiovascular disease.⁸ Established therapies to lower LDL-C levels include hydroxymethylglutaryl Co-A reductase inhibitors (statins), bile acid sequestrants, ezetemibe, LDL-C apheresis

and ileal bypass surgery. Statins however remain the predominant means of successful LDL-C lowering with an abundance of clinical and mechanistic evidence of the favourable impact these agents have upon atherosclerosis regression, and primary and secondary prevention.

Hydroxymethylglutaryl Co-A reductase is the rate limiting enzyme in the pathway leading to the endogenous synthesis of cholesterol by the liver. Inhibition of this enzyme results in the up-regulation of hepatic LDL receptors, with the subsequent removal of LDL from the circulation. Statins are well tolerated, and result in substantial inhibition in plasma LDL-C levels, coupled with modest elevations in HDL-C levels. A minority of patients develop elevations in hepatic transaminases and myositis, while rhabdomyolysis is exceedingly rare.

Statins have resulted in relative risk reductions of 20–40% of both primary^{10–12} and secondary cardiovascular events.^{13–17} The West Of Scotland Coronary Prevention Study (WOSCOPS) was the first primary prevention study that highlighted a 31% and 33% reduction of fatal and non-fatal coronary events respectively in 6595 randomized middle aged males (whose total cholesterol was greater than 6.5 mmol/L) who took pravastatin for 5 years.¹⁰ Following WOSCOPS, the AFCAPS/TextCAPS trial randomized 6605 patients with a mean total cholesterol level of 5.7 mmol/L to lovastatin or placebo. After 5 years follow-up, lovastatin reduced the combined end point of sudden death, myocardial infarction and unstable angina by 33%.¹¹ More recently, the JUPITER study randomized 17802 individuals without hyperlipidaemia (mean LDL-C less than 3.4 mmol/L) but with an elevated high-sensitive C-reactive protein (hsCRP) of greater than 2 mg/L to daily rosuvastatin 20 mg or placebo. The trial was halted prematurely after a median follow-up

of 1.9 years due to the rosuvastatin group experiencing a 23% relative risk reduction in the combined primary endpoint of myocardial infarction, stroke, arterial revascularisation, hospitalisation for unstable angina or death from cardiovascular causes.¹² This trial therefore highlighted the primary benefit of LDL-C lowering in patients with systemic inflammation.

The Scandinavian Simvastatin Survival Study (4S) randomized 4444 patients with established coronary artery disease and fasting total cholesterol between 5.5 to 8 mmol/L to treatment with simvastatin or placebo. After 5.4 years, the primary end point of all-cause mortality was reduced by 30% with simvastatin, with similar reductions in myocardial infarction and stroke.¹³ Similar magnitudes of reduction in mortality and myocardial infarction were seen in the Cholesterol and Recurrent Events (CARE) and Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) studies, which together evaluated the benefit of pravastatin versus placebo in over 13000 patients with prior myocardial infarction over a 5-year period.^{14,16} Additionally, the Heart Protection Study (HPS) randomized 20536 patients with established atherosclerotic CVD (or high-risk equivalents on the basis of diabetes mellitus) and total cholesterol greater than 3.5 mmol/L to treatment with simvastatin or placebo.¹⁵ Significant reductions in all-cause mortality (13%), cardiovascular mortality (17%), coronary events (27%) and stroke (25%) were found in the simvastatin group.

Regression of atherosclerosis within the coronary vasculature is a validated surrogate end-point of the clinical event reductions seen with statin therapies. Studies employing intravascular ultrasound (IVUS) have also highlighted the benefits of LDL-C lowering upon the coronary vessel wall. A consistent finding observed in the IVUS trials is the strong linear relationship between

mean LDL-C levels achieved on statin therapy and the median progression-regression rate of atherosclerosis. In the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) study, halting of disease progression was achieved with aggressive LDL-C lowering to 2.0 mmol/L with atorvastatin (80 mg/day), as compared with plaque progression seen in those patients randomized to moderate LDL-C lowering with pravastatin 40 mg/d who achieved a mean LDL-C of 2.9 mmol/L.¹⁸ The ASTEROID (A Study To Evaluate the effect of Rosuvastatin On Intravascular ultrasound –Derived coronary atheroma burden) study was the first large scale trial to show that plaque regression could be achieved by intensive LDL-C lowering to levels lower than achieved in REVERSAL. Rosuvastatin 40 mg/d lowered LDL-C levels to 1.6 mmol/L, and reductions in all volumetric measures of plaque burden was achieved.¹⁹ More recently, a pooled analysis of more than 4000 patients who underwent serial IVUS coronary imaging in 6 trials has demonstrated a direct relationship between the baseline plaque burden, its progression and major adverse cardiovascular events.²⁰

Although the clinical benefit seen in statin trials is able to be predicted from the degree of LDL-C lowering, statins are thought to exert vasculoprotective effects mediated by a variety of mechanisms other than direct LDL-C lowering. These suggested pleiotropic mechanisms include anti-thrombotic, anti-inflammatory, antioxidant, vasodilatory and anti-proliferative effects. Although such effects have been studied previously, only the anti-inflammatory CRP-lowering effects have been systematically evaluated in large scale clinical trials.

A major benefit of statin therapy is found in those patients with a high inflammatory state. Post hoc analyses of the CARE study found that those subjects with circulating biomarkers greater than the 90th percentile

had the greatest risk of recurrent events, and the greatest benefit from pravastatin occurred in this group.²¹ Further insights from REVERSAL revealed the superior CRP-lowering effects of atorvastatin over pravastatin. It is likely that this greater degree of anti-inflammatory effects exerted by atorvastatin contributed to a halting of atherosclerosis progression,²² whereby the CRP reductions correlated directly with changes in atheroma volume seen with IVUS. The PROVE-IT (PRavastatin Or atorVastatin Evaluation and Infection Therapy) study complimented the imaging findings from REVERSAL using the identical regimen of statin therapy in a large cohort of patients following an acute coronary syndrome (ACS), with the atorvastatin group experiencing significantly reduced clinical event rates.²³ It is yet to be shown as to whether CRP exerts direct effects upon plaque biology, and appropriately designed clinical trials will need to be undertaken to study the clinical effects of new molecules that directly target CRP.

The pleiotropic effects of statins have been postulated to result in plaque stabilization, which renders the plaque less likely to rupture to cause clinical events. Modulation of endothelial dysfunction and the anti-inflammatory properties of statins have been demonstrated within a few hours following statin administration. As a result, the effects of statins have been studied early in the setting of ACS or prior to elective percutaneous coronary intervention (PCI) in stable patients. Patients with ACS present a relatively high risk of recurrent adverse cardiovascular events. Hence, the early intensive use of statins may improve clinical outcomes and as such, statins have recently been included in the treatment guidelines for ACS.²⁴ The early benefit of statin therapy following ACS was demonstrated in The Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study.²⁵ This trial enrolled

3086 patients with ACS and randomized this group to atorvastatin 80 mg/d or placebo commenced within 24-96 hours following randomization. After 16 weeks, the atorvastatin group demonstrated a 14% relative risk reduction in the composite clinical endpoint of death, myocardial infarction, resuscitated cardiac arrest or admission for suspected ischaemia. Two recent meta-analyses of randomized controlled trials which evaluated for benefits of statins compared to placebo or usual care following ACS have highlighted that the real benefit of early statin therapy takes at least 4-6 months to become evident, with the significant benefits predominantly limited to reductions in unstable angina.²⁶

A number of studies have also investigated the effects of high-dose statin loading upon the incidence of periprocedural myocardial infarction in the setting of PCI. A large series of patients undergoing elective PCI (n = 5052), found that patients treated with statins at the time of procedure had a significant mortality reduction at 30 days (0.8% vs 1.5% in statin naive patients; p = 0.048); with this benefit being maintained at 6 month follow-up (2.4% vs 3.6%; p = 0.046).²⁷ Furthermore, in a series of 1552 patients, those patients that had initiated statin therapy prior to the procedure (39.6% of the study group) had a significantly lower incidence of periprocedural myocardial infarction (5.7% vs 8.1% in statin naive; p = 0.038) with a mortality benefit seen at 1 year (3.4% vs 6.9%; p = 0.003).²⁸ Statin pretreatment was predictive of survival chiefly in patients within the highest CRP quartile. The Atorvastatin for Reduction of Myocardial Damage During Angioplasty (ARMYDA) trial was the first randomized prospective, placebo controlled, double-blind study that demonstrated a beneficial effect of statin pretreatment in preventing myocardial damage following PCI.²⁹ Patients with chronic stable angina (n = 153) were randomized to

atorvastatin 40mg/d commencing 1 week pre-procedure versus placebo. Periprocedural myocardial infarction was detected in 5% of atorvastatin-treated patients compared to 18% in the placebo arm (p = 0.025). The ARMYDA ACS trial randomized 171 patients with ACS to receive placebo or atorvastatin loading (80 mg 12 hours before coronary angiography and a 40 mg dose 2 hours before intervention).³⁰ The primary composite endpoint of 30 day death, myocardial infarction and need for repeat target vessel revascularisation occurred in 5% of the treatment group compared to 17% of the placebo group (p = 0.04), with multivariate analysis indicating that atorvastatin pretreatment was associated with an 88% relative risk reduction of 30-day events. Furthermore, the ARMYDA RECAPTURE study showed that acute statin preloading prior to PCI in patients on chronic statin therapy had a protective effect with the combined endpoint of 30 day death, myocardial infarction and target vessel revascularisation occurring in 3.7% of patients in the re-load group vs 9.4% in the placebo group (p = 0.037); a 50% relative risk reduction on multivariate analysis.³¹ Both the ARMYDA ACS and ARMYDA RECAPTURE trial 30 day combined endpoints were largely driven by a significant reduction in periprocedural myocardial infarction. Collectively, this data highlights that statin pretreatment is a low risk yet highly effective therapy of 'plaque' and 'vessel' stabilisation, mediated perhaps via a number of pleiotropic effects, in both stable and unstable patients undergoing coronary intervention, regardless of whether patients are statin naive or not.

The vasculoprotective effects of statins also extends to the perioperative period during noncardiac surgery. A retrospective case-control study of 2816 patients who underwent major non-cardiac vascular surgery was the first study to show a 4-fold

significant reduction in all-cause mortality during the perioperative period.³² Soon after, the first prospective, placebo-controlled, blinded, randomized controlled trial evaluating the effects of 2 months of statin treatment upon perioperative cardiovascular complications after vascular surgery showed that the combined primary endpoint (cardiac death, nonfatal myocardial infarction, stroke or unstable angina) at 6-months was 3-fold higher with placebo than with atorvastatin 20 mg/d.³³ A number of retrospective studies have also evaluated the effects of statin therapy upon perioperative complications in patients undergoing noncardiac surgery. A large cohort (n = 780591) of patients undergoing noncardiac surgery found that in those 70159 statin users, there was a significant 1.4-fold reduced risk of in-hospital mortality.³⁴ The Statins for Risk Reduction in Surgery (STARRS) study assessed the effect of statins on cardiac complications in 1163 patients undergoing vascular surgery.³⁵ This study found a significantly lower perioperative complication rate in the statin group compared to statin non-users (adjusted OR 0.52, 95% CI 0.35-0.77). Furthermore, the long-term benefit of statins was observed in 510 patients undergoing successful abdominal aortic aneurysm surgery, with a significant reduction in all-cause mortality (18% vs 50%; p<0.001) seen in statin users compared to non-statin users over a median period of 4.7 years.³⁶ Although a risk of statin-induced myopathy exists in the surgical group of patients taking statins, this risk is considered relatively modest compared to the benefits of statins in reducing perioperative cardiac events. Also noteworthy is the evidence that suggests that statin therapy should remain uninterrupted (if possible) during the perioperative period. Due to the lack of availability of intravenous formulations, statin interruption, however, is common and usually unintended.

TABLE 5.2: LDL-C lowering summary points

- Statins are the most effective means of LDL-C lowering
- Statins inhibit the rate limiting enzyme in cholesterol synthesis
- Statins also achieve minor elevations of HDL-C, modest reductions of TGL levels
- 20%-30% reduction of events in primary prevention studies
- 30%-40% reduction of events in secondary prevention studies
- Clinical benefit proportion to degree of LDL-C lowering
- Regression of coronary atherosclerosis achievable with substantial LDL-C lowering
- Pleiotropic benefits of statins may contribute to benefit seen during ACS, peri-procedural administration during PCI, and peri-operatively for non-cardiac surgery

The complexity of HDL

Although the unequivocal benefit of LDL-C lowering has been demonstrated in a number of clinical trials, reductions in event rates by no more than 40% suggest that additional mechanisms are involved in mediating cardiovascular events, and that complementary strategies are required to achieve greater efficacy in cardiovascular risk reduction. HDL-C is emerging as an important therapeutic target for modulation of cardiovascular risk. Observational studies have suggested that the prevalence of low HDL-C levels (< 40 µg/dL, or 1.0 mmol/L) is greater in patients with established CAD, with numerous population studies also demonstrating an inverse relationship between HDL-C levels and prospective risk of CAD, regardless of the corresponding level of LDL-C.³⁷ HDL-C was found to be the strongest biochemical predictor of cardiovascular outcome in the Framingham study.³⁸ A pooled meta-analysis of four

population studies subsequently estimated that each 1 $\mu\text{g}/\text{dL}$ rise in levels of HDL-C was associated with a 2% to 3% reduction in cardiovascular risk.³⁹

High-density lipoprotein cholesterol possesses numerous anti-atherosclerotic properties, including the promotion of reverse cholesterol transport, protection of both LDL-C particles and endothelial cells from oxidative changes, inhibition of cytokine induced expression of endothelial cell surface adhesion molecules and the inhibition of the prothrombotic milieu associated with atheroma. Animal studies have provided support of these protective effects of HDL. Early studies showed that HDL infusions not only retard lesion formation but also promoted regression of established atherosclerotic plaque, with favourable effects also seen upon plaque composition.⁴⁰ These studies therefore provided robust pre-clinical evidence that raising HDL-C levels might be beneficial in humans.

There are a number of strategies that increase HDL-C levels. Non-pharmacological methods include weight loss, smoking cessation and mild alcohol consumption. Established pharmacological strategies include fibrates, statins and nicotinic acid, which raise HDL-C levels by 10-35%, 5-15% and 15-35% respectively. Fibrates have been shown to reduce clinical event rates in studies of primary and secondary prevention. The Helsinki Heart Study (HHS) demonstrated that an 11% increase in HDL-C independently predicted the 34% reduction in myocardial infarction and cardiovascular death with gemfibrozil. Each 1% increase in HDL-C was associated with a 3% reduction in cardiovascular risk.⁴¹ A similar benefit with gemfibrozil was observed in patients with established CAD and low HDL-C levels in the VA-HIT (Veterans Affairs High-Density Lipoprotein Intervention Trial), whereby the 6% rise in HDL-C predicted the 22%

reduction in myocardial infarction or cardiovascular death.⁴²

Apart from LDL-C lowering, statins modestly raise HDL-C levels. In a pooled analysis of four clinical studies, raising HDL-C was found to be an independent predictor of the benefits of statins in slowing progression of coronary atherosclerosis, with incremental benefit regression observed within those patients whose HDL-C rose by 7.5%, despite intensive LDL-C lowering.⁴³

Niacin is the most effective current method of raising HDL-C levels. Several studies have demonstrated that the use of niacin in combination with other lipid-modifying agents, had a substantial effect upon relative risk reduction and disease progression. The HATS (HDL in Atherosclerosis Study) showed that simvastatin and niacin raised HDL-C by 24%, lowered LDL-C by 42% and promoted regression of angiographically detectable CAD. Moreover, there was a profound 60% relative risk reduction in major adverse cardiac events.⁴⁴ The benefit of adding extended release niacin to statin therapy was also seen in the ARBITER-2 (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2) study, whereby an increase in HDL-C levels of 0.21 mmol/L slowed progression of carotid intimal-media thickness (CIMT) in patients with HDL-C levels below 1.2 mmol/L.⁴⁵ More recently, the addition of niacin (for HDL-C augmentation) was found to be superior to the addition of ezetimibe (for further LDL-C lowering) in a group of patients already on chronic statin therapy for CAD, whereby the niacin/statin group experienced significant regression of CIMT compared to the ezetimibe/statin group.⁴⁶ Intolerance due to flushing, which is mediated by activation of epidermal prostanoid receptors, continues to limit the widespread clinical use of effective doses of niacin. However, pharmacological strategies to inhibit these

epidermal prostanoid receptors in combination with the delivery of niacin therapy may hold promise for future trials employing niacin as an effective and well-tolerated anti-atherosclerotic therapy. Enthusiasm also exists for significantly raising HDL-C levels via the inhibition of cholesteryl ester transfer protein (CETP). In humans, CETP inhibition is capable of raising HDL-C levels by greater than 50% and reducing LDL-C levels by 20%. However the ILLUMINATE (Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events) trial was prematurely halted due to a higher clinical event rate seen in the patients administered Torcetrapib (CETP inhibitor).⁴⁷ These unexpected effects have been postulated to arise from activation of the renin-angiotensin system as well as a direct, unfavourable molecule-specific vasculotoxic effect of Torcetrapib itself.⁴⁸ The recent report of the safety of Anacetrapib, a next generation CETP inhibitor, has raised hopes that significant elevations in HDL-C levels via CETP inhibition will regress atherosclerosis and eventually result in reduced clinical event rates.⁴⁹

HDL comprise a heterogeneous group of particles, which vary in size, shape and content of both lipid and protein. Normal or elevated levels of HDL are not always atheroprotective in humans. The finding that greater than 40% of the clinical events observed in the Framingham cohort occurred in subjects with serum HDL-C levels greater than 1.01 mmol/L suggests that their HDL failed to possess the appropriate levels of protective properties.⁵⁰ The observation that HDL, isolated from subjects with CAD despite high HDL-C serum levels, promotes rather than inhibits monocyte chemotaxis in response to oxidised LDL-C, provided mechanistic evidence that HDL may be proatherogenic in some individuals.⁵¹ It remains to be established whether the size and composition of

HDL particles bears influence upon their functional properties. Contrasting reports from population studies have demonstrated that HDL particle size may influence prospective clinical risk. Furthermore, a potential relationship between HDL subclasses and cardiovascular risk has been reported to contribute to the relative benefit of various lipid-modifying therapies. In an exploratory analysis of VA-HIT, the generation of small HDL particles with gemfibrozil was demonstrated to independently predict protection from cardiovascular events.⁵² This may explain why a relatively small rise in HDL-C levels was associated with clinical benefit. The observation of benefit by raising levels of lipid-deplete HDL particles is consistent with their ability to remove excess cellular cholesterol, prevent LDL-C oxidation, rapidly improve endothelial function, and promote plaque regression in humans.⁵³

HDL therefore remains an attractive target for modification by therapies aimed to promote cardiovascular risk reduction. However, the complexity of HDL presents a major challenge in determining the optimal therapeutic approach. Although a number of groups have proposed specific HDL-C targets for treatment, there is no current evidence that treating to a particular target results in clinical benefit. At the minimum, it would seem that attempts to raise HDL-C levels above levels considered to be associated with an increase in cardiovascular risk (1.01 mmol/L in men and 1.28 mmol/L in women) would be prudent. However the emergence of the functional quality of HDL, rather than absolute HDL levels, is currently presenting a major challenge for future drug development programs. It is likely that raising the right type of HDL-C may have the greatest impact upon cardiovascular disease prevention.

TABLE 5.3: HDL-C cholesterol summary points

- Strongest independent predictor of events
- Numerous atheroprotective properties:
 - Promotes cholesterol efflux*
 - Anti-inflammatory actions*
 - Reduces oxidation of LDL-C*
 - Inhibits thrombogenicity*
- Elevated by weight loss, smoking cessation and mild alcohol consumption
- Therapeutically elevated by fibrates and nicotinic acid
- Novel therapeutic agents that elevate HDL-C levels and promote HDL-C functionality are currently being trialled in humans

The controversy of triglycerides

Despite extensive research, in the setting of clinical trials and epidemiologic studies, the exact role of serum TGL levels as an independent risk factor for CAD remains uncertain. Observational studies have produced data in support of the independent predictive value of fasting TGL levels for incident CAD. Graziano et al. investigated the interrelationships between fasting TGL and other lipid parameters, along with non-lipid risk factors, against the risk of myocardial infarction in 340 cases and 340 age-, gender- and community-matched controls. The relative risk of myocardial infarction was found to have a strong association with elevated fasting TGL levels that remained unaltered after controlling for other non-lipid risk factors; however despite remaining statistically significant, the strength of this association was attenuated somewhat after controlling for HDL-C.⁵⁴ Following this study, Jeppesen et al. examined the relationship between fasting TGL levels and ischaemic heart disease (IHD) risk in over 2,900 males in the Copenhagen Male Study, with 8-years of follow-up. Following adjustment of both

lipid and non-lipid risk factors, men in the middle and highest tertile of TGL levels had relative risks of IHD of 1.5 (95% CI, 1.0-2.3; $p = 0.05$) and 2.2 (95% CI, 1.4-3.4; $p < 0.001$) respectively, when compared with men in the lowest TGL tertile.⁵⁵ When TGL levels were stratified by HDL-C levels, the risk of IHD increased with increasing TGL within each HDL-C level. Similarly, the larger Prospective Cardiovascular Munster study involving 4,849 middle-aged men who were followed for 8-years found TGL levels to be an independent risk factor for CAD irrespective of HDL- or LDL-C levels.⁵⁶

Therefore there is no clinical trial that has been designed to specifically address the issue of TGL lowering upon incident cardiovascular events. Although patients enrolled in the HHS experienced a 35% reduction in TGL levels, it was the 11% increase in HDL-C levels that predicted the 34% relative risk reduction in the rate of myocardial infarction.⁴¹ Limited data therefore exists from clinical trials to suggest that the specific lowering of TGL levels, independent of concomitant HDL-C raising/LDL-C lowering, will result in reduced clinical event rates within patients with normal or elevated LDL-C levels. Although current guidelines do not mandate screening for elevated TGL levels within the general population, TGL levels in patients afflicted with CAD (or CAD risk equivalent) may provide valuable prognostic information for therapeutic decision-making. At this point the presence of mild to moderate hypertriglyceridemia identifies a patient who requires more intensive management of LDL-C, with treatment guidelines advocating initiation or intensification of statin therapy as first line treatment.

Hypertension

Epidemiologic studies have established a direct relationship between both systolic and

diastolic blood pressures and cardiovascular events. The strongest relationship lies between hypertension and cerebrovascular disease. Framingham data predict the lifetime risk of developing hypertension to be about 90% by the age of 65 years.⁵⁷ The Multiple Risk Factors Intervention Trial (MRFIT) demonstrated a continuous and graded relationship between both systolic and diastolic blood pressures and death due to both CAD and stroke,⁵⁸ with the strength of this relationship greatest for systolic blood pressure. In addition, isolated systolic hypertension, the commonest form of hypertension, portends a 2.5-fold greater risk of cardiovascular disease compared with matched, normotensive patients.

Hypertension alters shear forces within the vascular lumen. Steady laminar flow stimulates endothelial cellular functions which maintain vascular tone, thrombogenicity and regulated permeability. The mechanotransduction of these altered shear-stress signals arising from the endothelial surface result in a number of changes contributing towards atherogenesis, including altered gene expression, as well as changes to vascular regulatory substances including nitric oxide, endothelin and angiotensin II.

The use of anti-hypertensive therapy for primary prevention reduces cardiovascular events. A meta-analysis of randomised controlled trials involving the reduction of systemic hypertension in primary prevention revealed a 21% risk reduction in events attributed to CAD and a 37% reduction in the incidence of stroke.⁵⁹ The Hypertension Optimization Trial (HOT) randomised patients with hypertension to therapy aimed at three groups of blood pressure targets. Analysis revealed the lowest incidence of cardiovascular events in those with a mean diastolic blood pressure of 82.6 mmHg, supporting aggressive lowering of blood pressure into the 'normal' range.⁶⁰

The Heart Outcome Prevention Evaluation (HOPE) study supports the use of angiotensin converting enzyme (ACE) inhibition in all high risk patients. Despite the minimal blood pressure reduction seen in the ramipril arm, the use of an ACE inhibitor reduced the composite vascular end point by 22%, supporting the critical role played by the renin-angiotensin system in the promotion of atherogenesis.⁶¹ The second Australian National Blood Pressure Study also highlighted the benefit of an ACE inhibitor-based anti-hypertensive regimen significantly lowering cardiac death in the elderly population as compared to a diuretic-based regimen.⁶² The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT) reported no overall differences in CAD outcome among patients treated with a diuretic-based compared to a calcium channel blocker- or an ACE inhibitor-based treatment program.⁶³ However, patients in the diuretic group experienced fewer episodes of heart failure than in the calcium channel blocker group. Although The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) (National Heart, Lung, and Blood Institute. National Blood Pressure Education

TABLE 5.4: Hypertension summary points

- Strong independent risk factor
- Small reductions in blood pressure result in marked reduction in clinical events
- Reduction of blood pressure to the normal range results in the least number of clinical events; further reductions may be deleterious
- Blood pressure lowering per se is of utmost importance, irrespective of the choice of anti-hypertensive agent
- ACE inhibition reduces cardiovascular events in all high-risk patient groups, regardless of baseline blood pressure

Program, 2003) supports thiazide diuretics as first-step drug of choice in most hypertensive patients, what is clear from the wealth of trial data is that blood pressure lowering per se is of greater importance in reducing cardiovascular event rates rather than the choice of agent(s) used.

RISK FACTOR MODIFICATION IN THE DIABETIC PATIENT

Glycaemic Control

The incidence of diabetes continues to increase worldwide, predominantly due to the significant rise in the prevalence of type 2 diabetes mellitus, which now accounts for over 90% of all diagnosed cases. The major cause of morbidity and mortality in subjects with diabetes is attributed to atherosclerosis, particularly CAD. In subjects with type 2 diabetes, it is well established that there is a two- to four-fold increased risk of CAD, peripheral arterial disease and cerebrovascular disease than compared with matched non-diabetic controls. This persists despite accounting for other traditional cardiovascular risk factors such as hypertension, smoking and dyslipidaemia. Accordingly, treatment guidelines now consider the presence of diabetes to be an atherosclerosis equivalent, and suggest that diabetics should be treated in a similar fashion as those with established clinical cardiovascular disease in terms of risk factor control.⁶⁴

A number of direct and indirect pathways contribute towards atherogenesis in diabetics. Indirect pathways that are promoted by hyperglycaemia include worsening of dyslipidaemia (development of atherogenic dyslipidaemia; small dense LDL-C particles, reduced HDL-C levels and elevated TGL levels), sympathetic nervous system dysfunction and the development of renal dysfunction. Direct pathways (directly per-

taining to chronic hyperglycaemia) result in the overall reduction in the bioavailability of nitric oxide. The resultant endothelial dysfunction promotes vasoconstriction, pro-inflammatory and prothrombotic tendencies that contribute towards the progression of atheroma and subsequent atherothrombosis. Cholesterol and blood pressure lowering trials have demonstrated benefit in diabetic patients. Given the implicit relationship between hyperglycaemia and virtually all stages of atherogenesis, one would expect that the strict control of blood sugar levels would cause corresponding reductions in atherosclerotic cardiovascular disease. However clinical trials evaluating the impact of chronic, intensive glycaemic control upon cardiovascular disease have produced conflicting results, reflecting a complex interaction between glycaemic control and the atherosclerotic disease process.

Observational studies have tended to show a linear relationship between hyperglycaemia and cardiovascular mortality. However for levels of glucose at or below the threshold for the diagnosis of diabetes, the relationship with cardiovascular mortality is less clear-cut.^{65,66} Recently, the results of large-scale intervention trials examining the relationship between intensive glucose control and cardiovascular outcomes have been published. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial examined the effect of intensive glucose control (target HbA_{1c} under 6.0%, but achieving a mean level of 6.4%) versus standard therapy (targeting HbA_{1c} between 7.0-7.9%, achieving a mean level of 7.5%) in over 10,000 established type 2 diabetics.⁶⁷ An unexpected finding of a higher rate of cardiovascular mortality (34%, $p = 0.02$) and all-cause mortality (22%, $p = 0.04$) within the intensive glycaemic arm resulted in a premature halting of this study after a mean follow-up period of 3.5 years. Despite these

mortality rates, there was a non-significant trend towards a reduction in the primary outcome of the composite endpoint of non-fatal myocardial infarction, non-fatal stroke or cardiovascular death. Although the exact mechanisms of the resultant increase in mortality in this trial are unknown, an association between higher rates of severe hypoglycaemia within the intensive glycaemic control arm was reported, with patients with the highest baseline HbA_{1c} levels at greatest risk of hypoglycaemia compared to those with superior initial glycaemic control. In contradiction to ACCORD, the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicon Modified Release Controlled Evaluation) trial randomised over 11,100 type 2 diabetics to either intensive glucose control (achieving a mean HbA_{1c} of 6.5%) or standard control (achieving a mean HbA_{1c} of 7.3%).⁶⁸ After a mean follow-up period of 5 years, the composite primary endpoint of combined macrovascular and microvascular events was significantly attenuated in the intensive glucose control group. However this result was primarily driven by the significant reduction in microvascular endpoints, whereas there was no significant reduction in cardiovascular events.

In the United Kingdom Prospective Diabetes Study (UKPDS), 3,867 newly diagnosed type 2 diabetics were randomised to an intensive glycaemic control compared with conventional treatment policy.⁶⁹ Over the ensuing 10-year period of the trial, the intensively treated patients achieved a mean HbA_{1c} of 7.0% compared to a mean HbA_{1c} level of 7.9% in the conventionally treated group. The intensively treated patients experienced a 16% relative risk reduction of myocardial infarction which just failed to achieve statistical significance ($p = 0.052$) compared to the conventionally treated group. However the intensively treated group did experience a significant 25% reduction in microvascular

complications ($p = 0.01$). A sub-group of overweight individuals within the UKPDS study who were placed on metformin as part of their intensive glucose control regimen did experience a significant 39% reduction in myocardial infarction ($p = 0.01$) and a 36% reduction in all-cause mortality ($p = 0.01$). This data has been adopted to promote the use of metformin as a means of effectively reducing cardiovascular endpoints independently of glycaemic control. Following the publication of the UKPDS results, all surviving patients of this study entered into a post-trial monitoring program until 2007.⁷⁰ During this follow-up period, no attempts were made to continue the mode and intensity of glycaemic control according to their prior randomisation group. In the first year after entering the post-trial monitoring program, any differences in the HbA_{1c} between the previous 2 treatment groups was lost. Despite the rapid loss of glycaemic separation between the two groups in the post-trial follow-up program, a significant benefit of being previously randomised to an intensive glucose control regimen was still observed, whereby this group experienced a 15% lower rate of myocardial infarction ($p = 0.01$) as well as a 13% reduction in all-cause mortality ($p = 0.007$). Moreover, the prior reductions in microvascular endpoints as well as the benefits of metformin therapy were all maintained during this post-interventional follow-up study. These observations virtually mirror the results of the previously reported Diabetes Control and Complications Trial (DCCT); a 9-year trial highlighting the benefit intensive glycaemic control significantly delaying the development and progression of diabetes-related microvascular complications in type 1 diabetics, however failing to show any significant benefit upon cardiovascular events.⁷¹ Following completion of the DCCT, subjects were then followed by the Epidemiology of Diabetes Interventions

and Complications (EDIC) study.⁷² Again, differences in HbA_{1c} were quickly lost between the 2 treatment groups. The completion of the 11-year post trial observation period occurred in 2005, and despite the early loss in glycaemic separation between the prior 2 groups, the combined endpoint of cardiovascular events (non-fatal myocardial infarction, stroke or cardiovascular death) were reduced by 57% ($p = 0.02$) in the group of patients previously assigned to intensive glucose control.

The UKPDS follow-up study and the EDIC study suggest that the sustained, early intensive control of blood glucose levels eventually translates into a significant benefit upon the development of cardiovascular disease many years down the track. Mechanisms pertaining to this 'legacy' effect are currently unknown. At least 4 recently published meta-analyses (that have included the ACCORD and ADVANCE studies) have suggested that intensive versus standard glucose lowering reduces cardiovascular events without increasing cardiovascular or all-cause mortality.⁷³⁻⁷⁵ Therefore, an HbA_{1c} target of < 7.0% still remains an acceptable target for appropriate glucose control. However under certain circumstances, especially in the setting of newly diagnosed type 2 diabetes and in young patients without significant comorbidities, aiming for a lower HbA_{1c} level may represent an appropriate strategy to lower both microvascular and macrovascular complications.

Global risk factor reduction in diabetics

The greatest benefit for diabetic patients, in terms of cardiovascular risk factor reduction, has resulted from the aggressive modification of plasma lipoproteins and blood pressure. Diabetic dyslipidaemia, characterised by elevated TGL levels, reduced HDL-C levels

and the presence of small, dense LDL-C particles, represents a potent atherogenic stimulus. Weight loss and aggressive glycaemic control leads to an improvement of this lipid profile.⁶⁴ Statin trials have demonstrated greater relative risk reductions in diabetic subgroups, as have trials employing gemfibrozil.^{13,42} Although the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study did not show daily fenofibrate to significantly reduce the risk of the primary outcome of coronary events (death due to CAD or non-fatal myocardial infarction) in over 4800 type 2 diabetics, there was a primary reduction in the rate of coronary and non-coronary revascularisations as well as fewer non-fatal myocardial infarctions.⁷⁶ Moreover, fenofibrate therapy resulted in the improvement in a number of microvascular parameters. Furthermore, the ACCORD study group investigated whether combination therapy with statin plus fenofibrate, as compared with statin monotherapy, would further reduce the risk of cardiovascular disease in over 5,500 type 2 diabetics at high risk for cardiovascular events. The statin/fibrate combination did not reduce the rate of fatal cardiovascular events, non-fatal myocardial infarction, or non-fatal stroke as compared with statin therapy alone.⁷⁷ A recent meta-analysis (of 18 trials, over 45,000 patients) investigating the effects of fibrates on major clinical outcomes concluded that fibrates do reduce the risk of major cardiovascular events, largely driven by a 13% relative risk reduction (7-19) in coronary events ($p < 0.0001$).⁷⁸ Collectively, these trials suggest that although statin therapy should remain the cornerstone of treating dyslipidaemia in diabetics, diabetics with reduced HDL-C and elevated TGL levels may derive some additional benefit with the addition of fibrate therapy.

Similarly, lowering blood pressure is of utmost importance in diabetics for enhanced

cardiovascular risk reduction, portending a greater risk benefit in diabetics compared with non-diabetics. The blood pressure lowering sub-study of UKPDS confirmed a significant reduction in strokes (as well as microvascular endpoints) in those with aggressive blood pressure control (mean on-treatment blood pressure of 144/82 mmHg) compared with the group assigned less tight control (who achieved a mean blood pressure of 154/87 mmHg).⁷⁹ A similar observation was noted within the HOPE (Heart Outcomes Prevention Evaluation Study) study, with the benefit of ramipril seen in diabetic patients compared to those with established vascular disease.⁶¹ However, more recent attempts to define the optimum level of blood pressure control in diabetics has highlighted the complex relationship between blood pressure levels in diabetics and cardiovascular event rates. Until recently, it was widely felt that aggressive lowering of systolic blood pressure

below 135 mmHg in diabetics would be of further clinical benefit. However the results of the ACCORD study group collaborators found that in type 2 diabetics at high risk for cardiovascular events, intensive systolic blood pressure lowering to levels below 120 mmHg, as compared to less than 140 mmHg, did not reduce the rate of composite outcome of fatal and nonfatal major cardiovascular events.⁸⁰ Moreover, the patients assigned to intensive blood pressure lowering experienced significantly higher adverse event rates attributed to the antihypertensive treatment. This trial reinforced the notion that aggressive blood pressure lowering in diabetics to values below 130-135 mmHg may be problematic.

The metabolic syndrome

The metabolic syndrome refers to the co-existence of an atherogenic lipid profile, elevated blood pressure, and elevated plasma glucose, associated with abdominal obesity and insulin resistance.⁶⁴ Although a number of definitions exist, the most recent consensus from the International Diabetes Federation defines metabolic syndrome as the presence of central obesity (defined as waist circumference with ethnic specific values, or if body mass index exceeds 30 kg/m², then central obesity can be assumed) and any two of the following: (1) raised TGL levels (> 1.7 mmol/L), (2) reduced HDL-C levels (< 1.03 mmol/L in males and 1.29 mmol/L in females), (3) raised blood pressure (systolic blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg), (4) raised fasting plasma glucose level (> 5.6 mmol/L).⁸¹

Numerous studies have investigated the cardiovascular risk associated with metabolic syndrome, with ongoing debate regarding the prognostic significance of the metabolic syndrome for cardiovascular outcomes. A recent meta-analysis was conducted of

TABLE 5.5: Diabetes summary points

- Diabetes and insulin resistance are both strong risk factors for cardiovascular events
- Glycaemic control correlates with clinical outcome
- Aggressive glycaemic control reduces microvascular complications
- There is a more complex relationship between aggressive glycaemic control and reduction of macrovascular events
- Early, aggressive glycaemic control may have a longer term 'legacy' effect upon reduction in macrovascular events
- Metformin use in obese diabetics significantly lowers rate of myocardial infarction
- Statins remain the cornerstone of lipid management in diabetics
- Control of blood pressure equally important in diabetics; however aggressive lowering of systolic blood pressure to levels < 120 mmHg may be detrimental

the cardiovascular risk associated with the metabolic syndrome (as defined by the National Cholesterol Education Program), which found the presence of metabolic syndrome to be associated with a 2-fold increase in cardiovascular outcomes and a 1.5-fold increase in all-cause mortality.⁸² It remains unclear, however, as to the relative contribution of the individual components of the metabolic syndrome towards the mediation of cardiovascular risk. A recent study analysing the risk of myocardial infarction conferred by the metabolic syndrome and its individual components in multiple ethnic populations was recently undertaken. It was found that the risk of metabolic syndrome upon myocardial infarction is generally comparable to that conferred by some, but not all, of its component risk factors, whereby the association with myocardial infarction being similar to that of diabetes mellitus and hypertension.⁸³ Accordingly, a recent analysis of over 3450 patients who participated in 7 clinical trials that monitored coronary atheroma progression with IVUS found accelerated disease progression in those patients with the metabolic syndrome. However, after adjusting for its individual components, the presence of the metabolic syndrome itself was no longer found to be an independent predictor of disease progression.⁸⁴ In fact, further analysis of the same patient cohort found that patients with diabetes mellitus had greatest coronary plaque burden, greater plaque progression and lumen constriction than those categorised as having metabolic syndrome.⁸⁵ Further studies will need to be conducted to ascertain the candidate mechanisms by which metabolic syndrome mediates cardiovascular risk. However given the strong relationship between the presence of its component risk factors, the ideal anti-atherosclerotic approach tackling the metabolic syndrome would appear multi-factorial, in addition to weight loss and life-style measures.

FUTURE TARGETS

The current generation therapeutic approach for atherosclerotic cardiovascular disease prevention is essentially aimed directly at the modulation of known cardiovascular risk factors. Although these approaches have been successful in risk reduction, a substantial residual risk remains. Given our understanding of the implicit role of oxidative and inflammatory pathways in atherogenesis, therapies directly targeting these pathologic substrates represents a potential future challenge in achieving further risk reduction in the population. As a result, various novel therapeutic agents are undergoing clinical development. These include a number of anti-oxidant and anti-inflammatory therapies. It is likely that these therapeutic approaches will find their way into clinical practice.

CONCLUSION

Atherogenesis represents the culmination of a complex series of humoral events that promote the inflammatory cascade and thrombogenicity. The optimal therapeutic approach for both primary and secondary prevention of atherosclerosis still involves the traditional approach of global risk factor modification. However emerging therapies targeting novel markers of disease will be needed to tackle the residual burden of clinical events attributable to atherosclerosis despite contemporary anti-atherosclerotic therapies. Furthermore, emerging imaging and serum markers of atherosclerosis and its inflammatory content will enhance our risk prediction capabilities for cardiovascular events, as well as the ability to monitor response to anti-atherosclerotic therapies.

REFERENCES

1. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. *Circulation*. 2001; **104**(23): 2855–2864.
2. Calvet D, Touze E, Varenne O, Sablayrolles JL, Weber S, Mas JL. Prevalence of asymptomatic coronary artery disease in ischemic stroke patients: the PRECORIS study. *Circulation*. 2010; **121**(14): 1623–1629.
3. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). *J Vasc Surg*. 2000; **31**(1 Pt 2): S1–S296.
4. Ross R. Atherosclerosis – an inflammatory disease. *N Engl J Med*. 1999; **340**(2): 115–126.
5. Galis ZS, Khatry JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. *Circ Res*. 2002; **90**(3): 251–262.
6. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque hemorrhage and progression of coronary atheroma. *N Engl J Med*. 2003; **349**(24): 2316–2325.
7. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. *Circulation*. 2001; **104**(3): 365–372.
8. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. *JAMA*. 1987; **257**(16): 2176–2180.
9. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. *Lancet*. 1986; **2**(8513): 933–936.
10. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med*. 1995; **333**(20): 1301–1307.
11. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM, Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA*. 1998; **279**(20): 1615–1622.
12. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008; **359**(21): 2195–2207.
13. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994; **344**(8934): 1383–1389.
14. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention

- with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med.* 1998; **339**(19): 1349–1357.
15. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet.* 2002; **360**(9326): 7–22.
 16. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med.* 1996; **335**(14): 1001–1009.
 17. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med.* 2005; **352**(14): 1425–1435.
 18. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. *JAMA.* 2004; **291**(9): 1071–1080.
 19. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. *JAMA.* 2006; **295**(13): 1556–1565.
 20. Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, Uno K, Tuzcu EM, Nissen SE. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. *J Am Coll Cardiol.* 2010; **55**(21): 2399–2407.
 21. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. *Circulation.* 1998; **98**(9): 839–844.
 22. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. *N Engl J Med.* 2005; **352**(1): 29–38.
 23. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med.* 2004; **350**(15): 1495–1504.
 24. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, Jr., Chavey WE, 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC, Jr., Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American

- College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *J Am Coll Cardiol.* 2007; **50**(7): e1–e157.
25. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA.* 2001; **285**(13): 1711–1718.
 26. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, Kayikcioglu M, Arntz HR, den Hartog FR, Veeger NJ, Colivicchi F, Dupuis J, Okazaki S, Wright RS, Bucher HC, Nordmann AJ. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. *JAMA.* 2006; **295**(17): 2046–2056.
 27. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, Ellis SG. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. *Circulation.* 2002; **105**(6): 691–696.
 28. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, Ellis SG. Relation of inflammation and benefit of statins after percutaneous coronary interventions. *Circulation.* 2003; **107**(13): 1750–1756.
 29. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. *Circulation.* 2004; **110**(6): 674–678.
 30. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. *J Am Coll Cardiol.* 2007; **49**(12): 1272–1278.
 31. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. *J Am Coll Cardiol.* 2009; **54**(6): 558–565.
 32. Poldermans D, Bax JJ, Kertai MD, Krenning B, Westerhout CM, Schinkel AF, Thomson IR, Lansberg PJ, Fleisher LA, Klein J, van Urk H, Roelandt JR, Boersma E. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac


- vascular surgery. *Circulation*. 2003; **107**(14): 1848–1851.
33. Durazzo AE, Machado FS, Ikeoka DT, De Bernoche C, Monachini MC, Puech-Leao P, Caramelli B. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. *J Vasc Surg*. 2004; **39**(5): 967–975; discussion 975–966.
 34. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. *JAMA*. 2004; **291**(17): 2092–2099.
 35. O’Neil-Callahan K, Katsimaglis G, Tepper MR, Ryan J, Mosby C, Ioannidis JP, Dianas PG. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. *J Am Coll Cardiol*. 2005; **45**(3): 336–342.
 36. Kertai MD, Boersma E, Westerhout CM, van Domburg R, Klein J, Bax JJ, van Urk H, Poldermans D. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. *Am J Med*. 2004; **116**(2): 96–103.
 37. Rubins HB, Robins SJ, Collins D, Iranmanesh A, Wilt TJ, Mann D, Mayo-Smith M, Faas FH, Elam MB, Rutan GH, et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. *Am J Cardiol*. 1995; **75**(17): 1196–1201.
 38. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease – the Framingham Heart Study. *Can J Cardiol*. 1988; **4** Suppl A: 5A–10A.
 39. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Jr., Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. *Circulation*. 1989; **79**(1): 8–15.
 40. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. *J Clin Invest*. 1990; **85**(4): 1234–1241.
 41. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. *N Engl J Med*. 1987; **317**(20): 1237–1245.
 42. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N Engl J Med*. 1999; **341**(6): 410–418.
 43. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. *JAMA*. 2007; **297**(5): 499–508.
 44. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS,

- Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med.* 2001; **345**(22): 1583–1592.
45. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. *Circulation.* 2004; **110**(23): 3512–3517.
46. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, Griffen L, Taylor AJ. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. *J Am Coll Cardiol.* 2010; **55**(24): 2721–2726.
47. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med.* 2007; **357**(21): 2109–2122.
48. Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). *Circulation.* 2008; **118**(24): 2506–2514.
49. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P. Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. *N Engl J Med.* 2010; **363**(25): 2406–2015
50. Kwiterovich PO, Jr. State-of-the-art update and review: clinical trials of lipid-lowering agents. *Am J Cardiol.* 1998; **82**(12A): 3U–17U; discussion 39U–41U.
51. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. *Circulation.* 2003; **108**(22): 2751–2756.
52. Otvos JD, Collins D, Freedman DS, Shalurova I, Schaefer EJ, McNamara JR, Bloomfield HE, Robins SJ. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. *Circulation.* 2006; **113**(12): 1556–1563.
53. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on

- coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. *JAMA*. 2003; **290**(17): 2292–2300.
54. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. *Circulation*. 1997; **96**(8): 2520–2525.
 55. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. *Circulation*. 1998; **97**(11): 1029–1036.
 56. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. *Eur Heart J*. 1998; **19** Suppl M: M8–14.
 57. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. *JAMA*. 2002; **287**(8): 1003–1010.
 58. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. *Arch Intern Med*. 1993; **153**(5): 598–615.
 59. He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. *Am Heart J*. 1999; **138**(3 Pt 2): 211–219.
 60. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet*. 1998; **351**(9118): 1755–1762.
 61. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*. 2000; **342**(3): 145–153.
 62. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ. A comparison of outcomes with angiotensin-converting – enzyme inhibitors and diuretics for hypertension in the elderly. *N Engl J Med*. 2003; **348**(7): 583–592.
 63. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002; **288**(23): 2981–2997.
 64. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*. 2002; **106**(25): 3143–3421.
 65. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW. Glycemic control and coronary heart disease risk in persons with and

- without diabetes: the atherosclerosis risk in communities study. *Arch Intern Med.* 2005; **165**(16): 1910–1916.
66. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Stern MP, Blair SN. Low fasting plasma glucose level as a predictor of cardiovascular disease and all-cause mortality. *Circulation.* 2000; **101**(17): 2047–2052.
67. Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Jr., Probstfeld JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med.* 2008; **358**(24): 2545–2559.
68. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2008; **358**(24): 2560–2572.
69. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet.* 1998; **352**(9131): 837–853.
70. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med.* 2008; **359**(15): 1577–1589.
71. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *N Engl J Med.* 1993; **329**(14): 977–986.
72. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med.* 2005; **353**(25): 2643–2653.
73. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet.* 2009; **373**(9677): 1765–1772.
74. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. *Ann Intern Med.* 2009; **151**(6): 394–403.
75. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycaemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. *Nutr Metab Cardiovasc Dis.* 2009; **19**(9): 604–612.
76. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet.* 2005; **366**(9500): 1849–1861.

77. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Jr., Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med.* 2010; **362**(17): 1563–1574.
78. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. *Lancet.* 2010; **375**(9729): 1875–1884.
79. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ.* 1998; **317**(7160): 703–713.
80. Cushman WC, Evans GW, Byington RP, Goff DC, Jr., Grimm RH, Jr., Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med.* 2010; **362**(17): 1575–1585.
81. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. *Lancet.* 2005; **366**(9491): 1059–1062.
82. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. *J Am Coll Cardiol.* 2010; **56**(14): 1113–1132.
83. Mente A, Yusuf S, Islam S, McQueen MJ, Tanomsup S, Onen CL, Rangarajan S, Gerstein HC, Anand SS. Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. *J Am Coll Cardiol* 2010; **55**(21): 2390–2398.
84. Bayturan O, Tuzcu EM, Lavoie A, Hu T, Wolski K, Schoenhagen P, Kapadia S, Nissen SE, Nicholls SJ. The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. *Arch Intern Med.* 2010; **170**(5): 478–484.
85. Bayturan O, Tuzcu EM, Uno K, Lavoie AJ, Hu T, Shreevatsa A, Wolski K, Schoenhagen P, Kapadia S, Nissen SE, Nicholls SJ. Comparison of rates of progression of coronary atherosclerosis in patients with diabetes mellitus versus those with the metabolic syndrome. *Am J Cardiol.* 2010; **105**(12): 1735–1739.



Cover diagram by David Heinrich of the *Medical Illustration and Media Unit, Flinders Medical Centre*. (See chapter 18)

MECHANISMS OF VASCULAR DISEASE

Edited by Robert Fitridge and Matthew Thompson

Chapter 1: Endothelium **Chapter 2:** Vascular smooth muscle structure and function **Chapter 3:** Atherosclerosis **Chapter 4:** Mechanisms of plaque rupture **Chapter 5:** Current and emerging therapies in atheroprotection **Chapter 6:** Molecular approaches to revascularisation in peripheral vascular disease **Chapter 7:** Biology of restenosis and targets for intervention **Chapter 8:** Vascular arterial haemodynamics **Chapter 9:** Physiological haemostasis **Chapter 10:** Hypercoagulable states **Chapter 11:** Platelets in the pathogenesis of vascular disease and their role as a therapeutic target **Chapter 12:** Pathogenesis of aortic aneurysms **Chapter 13:** Pharmacological treatment of aneurysms **Chapter 14:** Aortic dissection and connective tissue disorders **Chapter 15:** Biomarkers in vascular disease **Chapter 16:** Pathophysiology and principles of management of vasculitis and Raynaud's phenomenon **Chapter 17:** SIRS, sepsis and multiorgan failure **Chapter 18:** Pathophysiology of reperfusion injury **Chapter 19:** Compartment syndrome **Chapter 20:** Pathophysiology of pain **Chapter 21:** Postamputation pain **Chapter 22:** Treatment of neuropathic pain **Chapter 23:** Principles of wound healing **Chapter 24:** Pathophysiology and principles of varicose veins **Chapter 25:** Chronic venous insufficiency and leg ulceration: Principles and vascular biology **Chapter 26:** Pathophysiology and principles of management of the diabetic foot **Chapter 27:** Lymphoedema – Principles, genetics and pathophysiology **Chapter 28:** Graft materials past and future **Chapter 29:** Pathophysiology of vascular graft infections



BARR SMITH PRESS

An imprint of
The University of Adelaide Press